Gene Association Mapping in the Era of Next-Generation Sequencing and Systems Biology by Zhang, Tianxiao
Washington University in St. Louis
Washington University Open Scholarship
Arts & Sciences Electronic Theses and Dissertations Arts & Sciences
Summer 8-15-2016
Gene Association Mapping in the Era of Next-
Generation Sequencing and Systems Biology
Tianxiao Zhang
Washington University in St. Louis
Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open Scholarship. It has been accepted
for inclusion in Arts & Sciences Electronic Theses and Dissertations by an authorized administrator of Washington University Open Scholarship. For
more information, please contact digital@wumail.wustl.edu.
Recommended Citation
Zhang, Tianxiao, "Gene Association Mapping in the Era of Next-Generation Sequencing and Systems Biology" (2016). Arts & Sciences
Electronic Theses and Dissertations. 909.
https://openscholarship.wustl.edu/art_sci_etds/909
 WASHINGTON UNIVERSITY IN ST. LOUIS 
Division of Biology and Biomedical Sciences 
Human and Statistical Genetics 
 
Dissertation Examination Committee: 
John P. Rice, Chair 
Laura J. Bierut 
Donald F. Conrad 
Christina A. Gurnett 
Nan Lin 
Nancy L. Saccone 
 
 
Gene Association Mapping 
in the Era of Next-Generation Sequencing and Systems Biology  
by 
Tianxiao Zhang 
 
A dissertation presented to the  
Graduate School of Arts & Sciences 
of Washington University in 
partial fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
 
 
 
 
August 2016 
St. Louis, Missouri 
  
 
 
 
 
 
 
 
 
 
 
© 2016, Tianxiao Zhang 
 
  
 
ii 
Table of Contents 
List of Figures ................................................................................................................................ vi 
List of Tables ............................................................................................................................... viii 
Acknowledgments.......................................................................................................................... ix 
Abstract .......................................................................................................................................... xi 
Chapter 0 Prologue ..........................................................................................................................1 
Chapter 1 Overview .........................................................................................................................2 
1.1 Genetic Epidemiology : Its Origin, Definition, and Early Development ..........................2 
1.1.1 What is genetic epidemiology? ...................................................................................2 
1.1.2 Early genetic epidemiology studies: nature versus nurture. .......................................4 
1.2 Gene Mapping: From Linkage study to Genome-wide Association Study. ......................6 
1.2.1. Linkage and candidate gene based association study .................................................6 
1.2.2 Genome-wide association study .................................................................................7 
1.3 Next-Generation Sequencing based Gene Association Mapping: Promising and Pitfalls. ....9 
1.4 Genetic Epidemiology Studies using Insights of Biological Networks ...........................11 
1.4.1 GWAS, WGS and their discontents: hypothesis ―free‖ or ―engaged‖? ........................11 
1.4.2 Human gene networks: novel insights into the genetic epidemiology study of complex 
traits……………………........................................................................................................13 
1.5 Figures ..................................................................................................................................15 
1.6 Tables ...................................................................................................................................16 
Chapter 2: Application of Non-collapsing Methods to Gene-based Association Test ..................18 
2.1 Introduction ..........................................................................................................................18 
2.2 Materials and Methods .........................................................................................................19 
2.2.1 Model fitting and algorithms .........................................................................................19 
2.2.2 Data and computation ....................................................................................................21 
2.3 Results ..................................................................................................................................23 
2.4 Discussion and Conclusion ..................................................................................................24 
2.5 Figures ..................................................................................................................................27 
2.6 Tables ...................................................................................................................................29 
Chapter 3. Family-based Whole Exome Sequencing Study for Bipolar Disorder ........................31 
iii 
3.1 Introduction ..........................................................................................................................31 
3.1.1 Clinical and epidemiological characteristic of bipolar disorder ....................................31 
3.1.2 Gene association mapping of bipolar disorder: a brief review ......................................31 
3.2 Materials and Methods .........................................................................................................33 
3.2.1 Study subjects ................................................................................................................33 
3.2.2 Experimental methods ...................................................................................................34 
3.2.3 Statistical methods .........................................................................................................34 
3.3 Results ..................................................................................................................................35 
3.3.1 Results of linkage analysis ............................................................................................35 
3.3.2 Results of variants filtering ............................................................................................37 
3.4 Discussion and Conclusion ..................................................................................................37 
3.5 Figures ..................................................................................................................................41 
3.6 Tables ...................................................................................................................................45 
Chapter 4 Targeted Sequencing Identifies Genetic Polymorphisms of Flavin-containing 
Monooxygenase Genes Contributing to Susceptibility of Nicotine Dependence in European and 
African Americans .........................................................................................................................48 
4.1 Introduction ..........................................................................................................................48 
4.1.1 Clinical and epidemiological characteristic of nicotine dependence .............................48 
4.1.2 Gene association mapping of nicotine dependence: a brief review ...............................49 
4.2 Materials and Methods .........................................................................................................51 
4.2.1 Study subjects ................................................................................................................51 
4.2.2 Targeted sequencing of FMO1 and FMO3 ....................................................................51 
4.2.4 Quality control measures ...............................................................................................52 
4.2.3 Statistical methods and bioinformatics analysis ............................................................52 
4.3 Results ..................................................................................................................................55 
4.3.1 Variant-wise association of FMO genes and nicotine dependence ...............................55 
4.3.2 Haplotype based and gene-wise association of FMO genes and nicotine dependence .56 
4.3.3 Bioinformatics analysis .................................................................................................56 
4.4 Discussion ............................................................................................................................57 
4.5 Figures ..................................................................................................................................62 
4.6 Tables ...................................................................................................................................66 
iv 
Chapter 5 Evaluation and Optimization of Multiple Centrality Measures in Human 
Protein-Protein Interaction Network ..............................................................................................71 
5.1 Introduction ..........................................................................................................................71 
5.2 Materials and Methods .........................................................................................................72 
5.2.1 Construction of human protein-protein interaction network .........................................72 
5.2.2 Calculation of multiple centrality measures ..................................................................73 
5.2.3 Extraction of human essential gene sets ........................................................................73 
5.2.4 Comparisons and evaluations of different centrality measures .....................................76 
5.2.5 Logistic regression model by combination of multiple centrality measures .................77 
5.3 Results ..................................................................................................................................77 
5.3.1 Human protein-protein interaction network and essential gene sets .............................77 
5.3.2 Comparisons of the four centrality measures as indicators of biological significance .78 
5.3.3 Comparison and optimization of the four centrality measures using logistic 
model …………………………………………………………………………………….…78 
5.4 Discussion ............................................................................................................................79 
5.5 Figures ..................................................................................................................................83 
5.6 Tables ...................................................................................................................................94 
Chapter 6 Centrality Pattern of Susceptibility Genes to Complex Disorders in Functional 
Specific Protein-Protein Interaction Sub-networks .......................................................................97 
6.1 Introduction ..........................................................................................................................97 
6.2 Methods and Materials .........................................................................................................98 
6.2.1 Construction of human PPI network and calculation of centrality ................................98 
6.2.2 Construction of brain function related sub-networks ....................................................98 
6.2.3 Extraction of susceptibility genes to complex disorders ...............................................99 
6.2.4 Statistical analyses .........................................................................................................99 
6.3 Results ................................................................................................................................100 
6.3.1 Construction of general human networks and brain function related sub-networks ...100 
6.3.2 Extraction of susceptibility genes to complex disorders and their centrality in multiple 
networks................................................................................................................................100 
6.3.3 Enrichment pattern of susceptibility genes to complex disorders in brain related 
sub-networks .........................................................................................................................101 
6.4 Discussion ..........................................................................................................................102 
v 
6.5 Figures ................................................................................................................................105 
6.6 Tables .................................................................................................................................116 
REFERENCES ............................................................................................................................120 
Curriculum Vitae .........................................................................................................................135 
 
 
  
vi 
List of Figures 
Chapter 1 
Figure 1.1 Histogram of GWAS publications by year……….…………………………..15 
Chapter 2 
Figure 2.1 Q-Q plot and histogram for the mixed effects model………………………...27 
Figure 2.2 ROC curves for four non-collapsing algorithms and two standard methods...28  
Chapter 3 
Figure 3.1 Pedigree structure of the BPD family sequenced in this study………………41  
Figure 3.2 Significant peak regions identified on chromosome 5 in three sets of linkage 
analysis…………………………………………………………………………………...42 
Figure3.3 Significant peak regions identified on chromosome 10 in all the ten sets of 
linkage analysis…………………………………………………………………………..43 
Chapter 4 
Figure 4.1 Regional association plots of FMO1-FMO3-FMO6P genomic region based on 
European Americans and African Americans……………………………………………62 
Figure 4.2 Protein-protein interaction network of FMO1………………………………..63 
Figure 4.3 Protein-protein interaction network of FMO3………………………………..64 
Figure 4.4 Protein-protein interaction network of FMO6P……………….………...…...65 
Chapter 5 
Figure 5.1 Scatter matrix for the four measurements of centrality………………………83 
Figure 5.2 Comparison of the average centralities of the four essential gene sets………84 
Figure 5.3 ROC curves of the average centralities aomng the four essential gene sets…85 
Figure 5.4 Comparison of the average centralities of the four essential gene sets using 
network constructed by 25% PPI data……………………………...……………………86 
Figure 5.5 Comparison of the average centralities of the four essential gene sets using 
network constructed by 50% PPI data……..……………………………………….……87 
Figure 5.6 Comparison of the average centralities of the four essential gene sets using 
network constructed by 75% PPI data……..……………………………………….……88 
Figure 5.7 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network……..………………………………………….……89 
Figure 5.8 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network constructed by 25% high quality PPI data……...…90 
vii 
Figure 5.9 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network constructed by 50% high quality PPI data………...91 
Figure 5.10 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network constructed by 75% high quality PPI data………...92 
Figure 5.11 AUC plot based on four essential gene sets………………………………...93  
Chapter 6 
Figure 6.1 Distribution of degree centrality for the three disorder categories in network 0, 
6, 12, 18, 24 and 30…………………………………………………………………….105  
Figure 6.2 Number of genes of susceptible gene sets in multiple brain related 
sub-networks……………………………………………………………………………106  
Figure 6.3 Median of degree centrality and their statistical significance for susceptible 
gene sets in multiple brain related sub-networks……………………………………….107 
Figure 6.4 Average of degree centrality and their statistical significance for susceptible 
gene sets in multiple brain related sub-networks……………………………………….108 
Figure 6.5 Median of degree centrality and their statistical significance for susceptible 
gene sets in multiple brain related sub-networks using 50% higher quality score PPI 
data……………………………………………………………………………………...109 
Figure 6.6 Gene number and centrality enrichment pattern for susceptibility genes to 
kidney related disorders in multiple brain related sub-networks……………………….110 
Figure 6.7 Gene number and centrality enrichment pattern for susceptibility genes to liver 
related disorders in multiple brain related sub-networks…………………………….....111 
Figure 6.8 Gene number and centrality enrichment pattern for susceptibility genes to lung 
related disorders in multiple brain related sub-networks………………………….……112 
Figure 6.9 Gene number and centrality enrichment pattern for susceptibility genes to skin 
related disorders in multiple brain related sub-networks………………………….……113 
Figure 6.10 Gene number and centrality enrichment pattern for susceptibility genes to 
pancreas related disorders in multiple brain related sub-networks………………..……114 
Figure 6.11 Line plots of the average degree centrality for susceptible genes in 
sub-network 0, 6, 12, 18, 24 and 30……………………………………………………115 
  
viii 
List of Tables 
Chapter 1 
Table 1.1 Selected human disorders/traits with estimated heritability…………………..16  
Chapter 2 
Table 2.1 Comparison of the statistical power of the four non-collapsing and two standard 
methods………………………………………………………………………………….29 
Chapter 3 
Table 3.1 Linkage analysis results of the ten replicate sets……………………………...45  
Table 3.2 Filtering procedure applied to the exome sequencing data from 6 BPD relative 
cases……………………………………………………………………………………...46  
Table 3.3 Summary information for 6 genetic variants identified after applying the 
filtering strategy…………………………………………………………………………47  
Chapter 4 
Table 4.1 Characteristics of study subjects………………………………………………66 
Table 4.2 Significant signals in variant-wise association analysis ……………………...67  
Table 4.3 Full results of gene-wise association analysis………………………………...69  
Chapter 5 
Table 5.1 Number of genes in each essential gene sets and the pattern of overlaps…….94  
Table 5.2 Summarized information of the four human gene network…………...….…...96 
Table 5.3 Detail information of AUC measures for different models…………………...96  
Chapter 6 
Table 6.1 Complex disorders selected for this research project……………...……...…116  
Table 6.2 FPKM thresholds and number of genes covered for the 31 networks 
constructed using STRING PPI data……………………………………………………117 
Table 6.3 Information of gene numbers of the three major susceptibility genes 
categories…………………………………………………………………………….....118  
Table 6.4 Top 20 genes with higher degree centrality in sub-network 30……………...119 
  
ix 
Acknowledgments 
I would first like to thank and acknowledge the work and guidance of my mentor, Dr. 
John P. Rice. He has been a tireless supporter and advocate for me throughout my graduate 
training, constantly seeking ways to improve my work and to provide opportunities for me to 
grow as a scientist. My thesis work has not been possible, if it were not for his guidance and the 
environment he provided. Working with John has been truly inspirational. 
I would also like to thank Dr. Christina A. Gurnett, Dr. Laura J. Bierut, Dr. Donald F. 
Conrad, Dr. Nan Lin, Dr. Nancy L. Saccone and Dr. Ingrid Borecki for serving (or had been 
served) on my thesis committee. I would like to give special thanks to Dr. Christina A. Gurnett 
for serving as a chair of my thesis committee and providing with very helpful advice at each 
stage of my thesis.  
I would also like to thank past and present members of John’s lab. If it were not for Xu 
Zhang, Fengxian Wang, Bill Howells, Lingwei Sun, Peter Jones, Sue Winkeler, Xiong Xu and 
Scott F. Saccone, it would have been much harder for me to carry out my graduate work.  
 
Tianxiao Zhang 
Washington University in St. Louis 
April 2016 
  
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my wife, Bo, and my son, Yiwei. 
 
 
  
xi 
ABSTRACT OF THE DISSERTATION 
Gene Association Mapping 
in the Era of Next-Generation Sequencing and Systems Biology  
by 
Tianxiao Zhang 
Doctor of Philosophy in Biology and Biomedical Sciences 
Human and Statistical Genetics 
Washington University in St. Louis, 2016 
Professor John P. Rice, Chair 
In the past decade, advancement of genotyping technology, first microarray then 
―next-generation‖ sequencing, has enabled scientists to examine the susceptible genes that 
contribute to the risk of complex disorders using a genome-wide, ―hypothesis free‖ strategy.  
However, despite this ―hypothesis free‖ label, these genome-wide approaches (including 
genome-wide association and whole genome sequencing studies) depend on two implicit 
assumptions. The first assumption is that the genetic risk of complex traits is contributed by 
independent genes/variants (assumption of independence).The second assumption is that 
different genes have equal potentiality to confer to the genetic predisposition of the complex 
traits (assumption of equality). Despite the huge success in susceptible gene association mapping 
in the last decade, more and more evidence has indicated that these two underlying assumptions 
of these genome-wide approaches may not be sound. Other than just studying one locus at a time, 
alternative methods which can carry out global analyses of biological molecules in populations 
xii 
have been developed to understand the influence of the whole biological system on complex 
traits. Network based approaches, in particular, have proven informative. 
This dissertation will cover a few important issues concerning sequencing based study design 
and its applications in chapter II, III and IV. Human protein-protein interaction network will be 
constructed and a few of human gene network related issues will be studied and discussed in 
chapter V and VI. Abstracts for each chapter were summarized as followed.  
Chapter 2: In this chapter, we proposed a two-stage, gene-based method for association mapping 
of rare variants by applying four different non-collapsing algorithms. Using the Genome 
Analysis Workshop 18 whole genome sequencing dataset of simulated blood pressure 
phenotypes, we studied and contrasted the false positive rate of each algorithm using receiver 
operating characteristic curves. The statistical power of these methods was also evaluated and 
compared through the analysis of 200 simulated replications in a smaller genotype data set. We 
showed that the Fisher’s method was superior to the other three 3 non-collapsing methods, but 
was no better than the standard method implemented with famSKAT.  
Chapter 3: In this chapter, we aimed to identify potential susceptibility variants for bipolar 
disorder via the combination of exome sequencing and linkage analysis on 6 related subjects 
from a four-generation family. Our study identified a list of five potential candidate genes for 
bipolar disorder. Among these five genes, GRID1 (Glutamate Receptor Delta-1 Subunit), which 
was previously reported to be associated with several psychiatric disorders and brain related 
traits, is of particular interest. Our findings suggest a potential role for these genes and the related 
rare variants in the onset and development of bipolar disorder in this one family.  
Chapter 4: In this chapter, we investigated the potential of FMO genes to confer risk of nicotine 
dependence via deep targeted sequencing in 2,820 study subjects comprising of nicotine 1,583 
xiii 
dependents and 1,237 controls from European and African Americans. Specifically, we focused 
on the two genomic segments including FMO1, FMO3 and the pseudo gene FMO6P, and aimed 
to investigate the potential association between FMO genes and nicotine dependence. We 
identified different clusters of significant common variants in European (with most significant 
SNP rs6674596, P=0.0004, OR=0.67, MAF_EA=0.14) and African Americans (with the most 
significant SNP rs6608453, P=0.001, OR=0.64, MAF_AA=0.1). Most of the significant variants 
identified were SNPs located within intronic regions or with unknown functional significance. 
Chapter 5: In this chapter, we aimed to investigate the followed three scientific questions: 1) Can 
centrality reflect the biological significance of genes in a general human gene network? 2) 
Among these four commonly used centrality measures, does any of them outperform others? 3) 
Will they do better if we combine several centrality measures together using machine learning 
algorithms? To answer these scientific questions, we constructed a comprehensive human 
gene-gene network using protein-protein interaction data. Four essential gene sets were extracted 
from a variety of data sources serving as true answers in the evaluation and optimization process. 
Our analytic results indicated that there is a connection between the essentiality and centrality of 
human genes. A pattern of strong correlations was identified among the four commonly used 
centrality measures for a general human PPI network and the performance of each centrality 
measure was similar to others serving as predictors of the essentiality of genes. The improvement 
of the prediction models was limited when we combined several different centrality measures.  
Chapter 6: In this chapter, we aimed to investigate the potential enrichment pattern in centrality 
of susceptible genes for certain complex disorders in a functional specific sub-network. Gene 
expression data of human brain tissue recorded in the Human Protein Atlas were extracted and 
utilized to construct a series of brain function specific sub-networks. Susceptible genes from 
xiv 
three categories of complex disorders, including neurodegenerative disorder, psychiatric disorder 
and non-brain related disorder, were extracted from the GWAS catalogue. We identified a 
significant enrichment pattern of high centrality of susceptibility genes contributing to 
neurodegenerative and psychiatric disorders in these sub-networks. Our findings indicate that 
susceptibility genes of complex disorder might have higher centralities in functional specific 
sub-networks.  
1 
Chapter 0: Prologue 
 
―On proceeding to the spot, I found that nearly all the deaths had taken place 
within a short distance of the pump. There were only ten deaths in houses situated 
decidedly nearer to another street-pump. In five of these cases the families of the 
deceased persons informed me that they always sent to the pump in Broad Street, as they 
preferred the water to that of the pumps which were nearer. In three other cases, the 
deceased were children who went to school near the pump in Broad Street...‖ 
—John Snow, On the Mode of Communication of Cholera, 1855 
 
―My experiments with single traits all lead to the same result: that from the seeds 
of hybrids, plants are obtained half of which in turn carry the hybrid trait (Aa), the other 
half, however, receive the parental traits A and a in equal amounts. Thus, on the average, 
among four plants two have the hybrid trait Aa, one the parental trait A, and the other the 
parental trait a. Therefore, 2Aa+A+a or A+2Aa+a is the empirical simple series for two 
differing traits.‖ 
—Gregor Mendel, Letter to Carl Nägeli, 1866 
 
―A LADY declares that by tasting a cup of tea made with milk she can 
discriminate whether the milk or the tea infusion was first added to the cup. We will 
consider this problem of designing an experiment by means of which this assertion can be 
tested.‖ 
—Sir Ronald A. Fisher, The Design of Experiments, 1935 
  
2 
Chapter 1: Overview 
1.1  Genetic Epidemiology : Its Origin, Definition, and Early 
Development 
1.1.1 What is genetic epidemiology? 
Genetic epidemiology, as the name suggests, is an inter-discipline that is related to 
both epidemiology and genetics. I would like to describe a genetic epidemiologist as an 
epidemiologist who tries to unravel the enigma of (human) genetics using the tool sets of 
statistics. In this sense, genetic epidemiology, as a field of study, can be traced back to 
three origins. The first one is modern epidemiology. The core methodology and 
terminology used in genetic epidemiology are directly borrowed from it. Another one is 
genetics. Unraveling the genetic (and the environmental) determinants of human traits 
and disorders are the major goals of genetic epidemiology. Last but not least, statistics. 
Statistics is the fundamental tool utilized in genetic epidemiology study, and statistical 
estimation is required in most, if not all, genetic epidemiology related publications. Just 
as other thriving disciplines, genetic epidemiology is also an evolving study subject that 
keeps on adapting to the progress of biomedical science in modern days. Besides the 
three origins I mentioned above, genomics and bioinformatics are also involved in 
genetic epidemiology studies in the 21
th
 century.  
From the perspective of epidemiology, there are mainly two kinds of study designs: 
observational and experimental. In observational studies, researchers only observe their 
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study subjects and do not intervene. While in experimental studies, a researcher, instead 
of observing from the sidelines, controls the factors affecting a certain case study [1]. 
Genetic epidemiology, as a concept used in this thesis (and in most academic scenarios), 
is strictly observational. This perspective actually provides us a chance to distinguish 
genetic epidemiology and human genetics. Human genetics offers a wider concept 
compared to genetic epidemiology. Besides observational studies (genetic epidemiology), 
it also includes experimental studies performed using model organisms. Both study 
designs have its advantage and disadvantage. Confounders (population stratification, e.g.), 
especially those unknown, can always be problematic for observational studies (genetic 
epidemiology). They place obstacles for the ―giant leap‖ from statistical association to 
causal inference. On the other hand, experimental studies (based on model organisms) 
could handle this confounding issue very well. However, generalization is a major weak 
point of these kinds of studies when researchers try to trace the significance of some 
causal variants identified in model organisms (mouse, e.g.) using gene 
knockout/knockdown technology back to human beings.  
Genetic epidemiology studies try to clarify the following logically ordered scientific 
questions about human traits\disorders:  
1) Does this trait/disorder have a pattern of familial aggregation (family clustering)?  
2) Can shared genes explain the familial aggregation? 
3) How much can these shared genes explain the familial aggregation? 
4) Where are these genes and how do they contribute to the trait/disorder? 
4 
A first observation of genetic related traits/disorders is always their familial 
clustering pattern. However, this pattern is not necessary due to shared genes but could 
also be share environments. Several study designs, including immigration studies and 
adoption studies, can provide a way to separate the genetic variance from the 
environmental variance. After knowing the fact that genes matter, the next question is 
that how much these genes could explain the familial clustering pattern. Twin studies are 
a common study design to answer this question. Once we know the phenotypic variance 
that could be explained by genetic variance, then where are these genes? Linkage studies 
and gene association mapping could answer this question. Genetic data are not needed to 
answer the first three questions. I will briefly discuss them in the next section.   
1.1.2 Early genetic epidemiology studies: nature versus nurture  
Before scientists took a great interest in it, family aggregation as an observation 
from everyday life has long been noticed and characterized in some idioms, such as Like 
father like son or A wise goose never lays a tame egg. The early genetic epidemiology 
studies can be traced back to the work of Francis Galton, who was half-cousin of Charles 
Darwin, in the 19
th
 century. Galton was interested in answering the question whether 
human traits were hereditary. He devoted most of his academic life to devise large-scale 
data collection of different measurements of human traits, from mental characteristic to 
intelligence. Galton proposed that if eminence was hereditary, there should be more 
eminent men among the relatives than among the general population, and the numbers of 
eminent relatives dropped off when going from first degree to second degree relatives, 
and from second degree to third [2]. This is a typical familial aggregation study design, 
although it is not enough to test whether a specific trait is hereditary because of the mixed 
5 
genetic and environmental variance. Galton recognized the limitations of his methods in 
his works, and believed the question could be better studied by comparisons of twins. He 
also proposed adoption studies.  
An Adoption study investigates the similarity between the adoptees and their 
biological and adoptive parents. The similarity between adoptees and their biological 
parents is expected to be heritable, while similarity with their adoptive parents is shared 
environmental effect. With this study design, an adoption study can separate the effects 
of heredity and environment. However, it is difficult to link an adopted child to their 
biological family. Therefore, a simplified version (familial design) is sometimes applied 
by comparing the non-biological siblings who are reared in the same household. 
Additionally, another study design, the so called ―immigration study‖ can do the same 
thing by comparing the phenotype of immigrants, populations in their original countries 
and populations in their resident country. The phenotypic similarity between immigrants 
and populations of their original country can be explained by the shared genetic 
background, while similarity with populations of their resident country can be explained 
by the shared environments.  
Both adoption and immigration studies could offer us a way to deduce whether 
observed variation in a particular trait is due to environmental or to biological factors 
(sometimes popularly expressed as the "nature versus nurture" debate). The next question 
would then be how much of the variation in a human trait is due to variation in genetic 
factors. The portion of phenotypic variance that can be explained by genetic factors is 
summarized as the concept of heritability. Traditionally, heritability can be estimated 
from empirical data and simple study designs, such as the correlation of offspring and 
6 
parental phenotypes, the correlation of full or half siblings, and the difference in the 
correlation of monozygotic (MZ) and dizygotic (DZ) twin pairs. In the past decades, the 
heritability of many human complex disorders/traits has been estimated and summarized 
them in Table 1.1. 
A major feature of these early epidemiology studies is that no genotypic data is 
involved. Therefore it is impossible to map the susceptible/causal genes that contribute to 
those human traits/disorders. This deficiency will only be remedied when there is a set of 
genetic markers which cover the human genome and a cost effective experimental 
technology to genotype them. The advancement of DNA technology in the 1980s and 
1990s meet these two conditions and enables the genetic epidemiologist to conduct 
research to finally locate the susceptible/causal genes in the human genome.  
1.2 Gene Mapping: From Linkage study to Genome-wide Association 
Study 
1.2.1. Linkage and candidate gene based association study 
The goal of a linkage study is to identify the genetic linkage between genetic 
markers and potential trait/disorder loci occurred during meiosis. The genetic linkage 
segment can range from a couple to a dozen of megabases (Mb), and this build-in 
mechanism determines that a linkage study can only identify a genetic locus that covers 
several Mbs on a chromosome. Short tandem repeats (STR), which are genetic 
polymorphisms that consist of a unit of 2 to 13 nucleotides repeated hundreds of times in 
a row on the DNA strand, is an efficient genetic marker for conducting linkage study. 
STRs are multi-allelic genetic markers, and that means they are much more informative 
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compared to single nucleotide polymorphisms (SNPs) of which most are biallelic. 
Genotying of 400 STRs is enough for a typical genome-wide linkage scan while it may 
take more than 3,000 SNPs to achieve the same statistical power. Compared to a linkage 
study, an association study, which is based on linkage disequilibrium (LD), is more 
accurate and can pinpoint the location of specific susceptible genes. Nevertheless, it was 
too expensive to have a half million SNPs genotyped for one subject when conducting a 
genome-wide association study (GWAS) in the 1990s. To make a compromise between 
the experimental costs and accuracy in gene association mapping, a very popular 
association mapping strategy back to the 1990s (and early 2000s) was to conduct a 
genome-wide linkage scan first, and the significant loci identified in the linkage study, 
which is a chromosomal region of around 10-20 cM, was scrutinized in a candidate gene 
based association study based on a set of dozens of SNPs selected within the candidate 
significant region (usually 10-20 genes). Although this study design is logically sound 
and financially feasible, it is not a systematic solution to identify genes for human 
complex disorders/traits. An insightful review published in 2012 estimated that the total 
money spent on candidate gene based association studies and linkage studies in the 1990s 
and the 2000s exceeded $250M, but had generated very limited findings compared to the 
findings of GWAS in its first five years (2007-2011, ) which also spend around $250M 
[3].  
1.2.2 Genome-wide association study 
Although the first GWAS results were published in 2005 and 2006, GAWS as a 
theoretical design had been proposed by Risch and Merikangas ten years earlier. In their 
1996 landmark paper, they showed that an association study performed with one million 
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variants genotyped in a set of unrelated subjects will be more powerful than the genome 
linkage scan that was widely utilized in gene association mapping studies at that time [4]. 
The breakthrough in SNP genotyping using microarray technology [5] finally turned this 
once theoretical design into a real one. The first published GWAS study was a study 
conducted on age-related macular degeneration (ARMD) [6]. What may amaze 
researchers today is that this study has successfully identified a significant locus (and it is 
proved that this locus contribute largely on the risk of ARMD) with around 100,000 
SNPs genotyped in only 96 cases and 50 controls [6]. After that, genome-wide 
association studies (GWAS) have rapidly become a standard method for discovering 
susceptible genes for a variety of complex disorders/traits, and it is widely believed to be 
a promising tool for identifying potential susceptible loci. So far, many GWAS studies 
are published annually. As of June, 2015, 2,414 GWA studies in total have been 
published [7]. Around 10,000 susceptible loci have been reported to be significantly 
associated with around 1,000 complex human traits/disorders [7]. Up to now, most of our 
knowledge of susceptible genes that contribute to the human complex disorders/traits was 
generated by GWAS.  
Despite undisputable successes of the genome-wide approach mentioned above, 
GWAS is sometime criticized for its focusing on common SNPs while ignoring rare and 
structural variants which may have large effects on complex traits[8][9][10]. 
Considerable evidence has shown that rare variants and structural variants may have 
significant effects on the onset and development of complex disorders, however, this 
evidence is selectively omitted and only common variants(minor allele frequency ≥ 0.01) 
are considered  in GWAS due to a pure statistical concern (to maximize the statistical 
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power in analysis) and genotyping technology limitations[11]. In the past six years, this 
challenge has been partly resolved by the development of sequencing technology. 
High-throughput sequencing technologies, or so called ―next-generation‖ 
sequencing(NGS) technologies, which process millions of sequence reads in parallel, 
provide monumental increases in speed and volume of generated data at a relatively 
acceptable cost[12][13]. Fewer GWAS were published annually since 2012, and this 
trend is coincidence with the popularity of sequencing based studies (Figure 1.1).  
1.3 Next-Generation Sequencing based Gene Association Mapping: 
Promising and Pitfalls 
Advancement of DNA genotyping technology has greatly promoted the research of 
genetic epidemiology and gene mapping in the last 30 years. Cheaper and faster DNA 
genotyping technology enables some once theoretically genetic epidemiology study 
designs, such as genome-wide linkage scan and GWAS, to be done. In this sense, NGS 
enables the researchers to capture the information of every single variation in the human 
genome. The 1000 genome project, a public population genetics project using NGS 
technology, has shown that there are more than 88 million variations, including 84.7 
million SNPs, 3.6 million short insertions/deletions (indels) and 60,000 structural variants, 
in the human genome [14]. Compared to this number, genome linkage scan only involves 
about 400 STRs and GWAS only examines 300,000~600,000 common SNPs. The idea of 
a whole genome sequencing (WGS) study is preferable to the previous gene mapping 
study design in completeness by measuring every variation in human genome. Several 
WGS studies focusing on relatively small number of subjects with psychiatric disorders 
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[15][16] and cancers [17] [18][19] have been published in high profile academic journals 
and novel findings were reported. 
Despite its advantage and promising future mentioned above, sequencing-based 
association mapping, at least in its current stage, still has two issues left unaddressed. 
Firstly, unlike linkage and GWAS, there are no matured statistical analysis methods can 
be applied to sequencing data. A major challenge for sequencing based data is that there 
are a lot of genetic variants with low allele frequency. That means the single marker 
based analysis methods utilized in GWAS cannot be applied directly to sequencing-based 
data due to lack of statistical power. A common approach to overcome this issue is to 
collapse rare variant information within specific genomic regions (genes, for example), 
and these methods are generally called collapsing methods [20][21][22]. I will provide 
more details about these collapsing methods and conducted a comparison study to 
investigate the efficient of multiple sequencing data analysis methods in Chapter II of this 
thesis. The second issue concerns money. Although NGS has greatly reduced the 
experimental cost of human genome sequencing, it still takes 5-10 times of experimental 
cost to have a human genome sequenced (WGS) compared to genotyped by a microarray 
panel (used in GWAS). Two other study design can partly address this issue. The first 
one is instead of performing WGS on study subjects, researchers can perform exome 
sequencing which only focuses on exonic regions of human genome (1% of the human 
genome). This strategy can retain a large amount of genetic information of significant 
functional regions while having a much lower experimental cost compared to WGS. I 
will present an exome sequencing based study on bipolar disorder in Chapter III. Another 
study strategy is to sequence a couple of targeted susceptible genomic regions. On one 
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hand, rare and structural DNA variants of targeted genomic regions can be thoroughly 
investigated through DNA sequencing, while on the other hand, the experimental cost can 
be restricted to a reasonable level. I will present a targeted sequencing study of nicotine 
dependence in Chapter IV.  
1.4 Genetic Epidemiology Studies using Insights of Biological Networks 
1.4.1 GWAS, WGS and their discontents: hypothesis “free” or “engaged” 
Genome-wide approaches are described as ―hypothesis free‖ study designs, because 
comparing to the candidate gene based approach, this study strategy does not need prior 
knowledge about the candidate genes. A genome-wide scale study enables the genotyped 
genetic markers to offer sufficient coverage to most of the human protein coding genes (if 
not all) [23]. The ―hypothesis-free‖ basis of genome-wide approaches offered the 
opportunity to overcome difficulties and obstacles imposed by the incomplete 
understanding of disease pathophysiology. However, despite this ―hypothesis free‖ label, 
these genome-wide approaches (including GWAS and WGS) are somewhat dependent on 
some underlying hypotheses.  
The first underlying assumption is that the genetic risk of complex traits is 
contributed independently by genes/variants (assumption of independence). For example, 
in GWAS, the simplest analysis strategy is to do logistic regression in a single-locus 
manner [23], and in association mapping based on DNA sequencing data, the so-called 
―collapsing method‖ was widely utilized for which variants information are often 
collapsed within a genomic region or gene and then each region/gene will be tested 
pointwisely [21].However, in the past decade, many studies of quantitative traits in 
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animal models suggest that epistatic interactions between loci are widespread[24][25][26], 
and various examples of gene-by-gene interactions for human complex traits have been 
identified[27].A research study using yeast strains provided an estimated importance of 
epistatic interactions for 46 highly heritable traits. It shows that the contribution of 
gene-gene interactions (including both two-loci interactions and high order interactions) 
varies from zero to ~50% and detected two-locus interactions explain only a minority of 
this contribution [28]. In this study, the researchers have used yeast, which is a simple 
unicellular organism, as their research subject. We can expect that in some higher level 
multi-cellular organisms such as mammals, the patterns of gene-gene interactions will be 
more complex. The second assumption is that for GWAS/WGS, different genes are 
considered to have equal potentiality to confer the genetic predisposition to the complex 
traits (assumption of equality). This assumption has been partly challenged by the 
evidence that susceptible genes often show a clustered pattern within certain biological 
pathways [29][30]. In addition, previous studies conducted in several different model 
organisms [31] have shown that highly connected proteins or ―hubs‖ are more likely to be 
encoded by essential genes which are necessary for fundamental processes in an 
organism and lead to pre- or neonatal lethality when disrupted.  
To conclude, all of the above evidence has indicated that genes are neither created 
equally nor perform their functions independently, and novel insights are needed for 
understanding the mechanisms of genetic predisposition for complex traits. Other than 
simply studying one locus at a time, alternative methods which can carry out global 
analyses of biological molecules in populations have been developed to understand the 
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influence of the whole biological system on complex traits[32][33]. Network based 
approaches, in particular, have proven informative.  
1.4.2 Human Gene Networks: Novel Insights into the Genetic Epidemiology Study of 
Complex Traits   
Human gene networks are graphical representations of the interactions between the 
genes. In a human gene network, genes are represented as nodes and the relationships 
among them as edges. Human gene networks can be divided into three categories: 1) 
Human gene networks derived from curated knowledge; 2) Human gene networks based 
on experimental data of physical interactions, and 3) those that are inferred from 
high-throughput data [31]. In the past decade, the most interesting finding of gene 
network analysis is that proteins that are encoded by essential genes tend to have high 
centrality degrees in the protein-protein interaction network. This feature was firstly 
identified in yeast [34][35]. Since then, several studies were conducted to focus on the 
phenotypes related to human diseases. Wachi et al. studied genes that are differentially 
expressed in lung squamous cancer tissues, and found that up-regulated genes in the 
cancerous tissues tended to be highly connected and central [36]. Another study in 2006 
investigated the network position of 346 genes that had been implicated in a 
comprehensive census of all human cancer genes. They showed that on average the 
proteins encoded by these genes tended to have twice as many interaction partners as 
noncancer related genes [37]. Nevertheless, in a 2007 published research paper, Goh et al. 
created a network of human disease/human gene associations, in which each genetic 
disease is connected to the genes known to cause it. They found that most of the disease 
genes have no tendency toward higher degree in the human protein-protein interaction 
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network [38].One possible explanation for this discrepancy among the studies above is 
that the former two studies focused on cancer genes in particular while Goh et al. 
investigated disease in general. 
Among all these early studies, a significant limitation is that all these studies have 
focused on cancer or Mendelian disorders, and the researchers have paid limited attention 
to complex disorders. This limitation can be justified by the specific time when these 
research projects were conducted. Most of the knowledge of susceptible genes on 
complex disorders has been generated after 2007 when GWAS become a standard genetic 
epidemiological research strategy on complex disorders. In addition, recent evidence of 
interactome networks in the last decade has also questioned the potential incompleteness 
in these previous studies. Large scale, comprehensive analysis incorporating with new 
findings obtained in the past decade is needed. In chapter 5 of this thesis, I will first 
examine the centrality measurements of genes as indicators of their biological 
significance in a human general gene network. Then, in chapter 6 I will explore the gene 
sets centrality feature for different complex disorders and functional pathways 
enrichment patterns in general human gene networks and disease-specific sub-networks. 
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1.5 Figures 
 
Figure 1.1 Histogram of GWAS publications by year. The publications of 2015 were 
included from January to June.   
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1.6 Tables 
Table 1.1 Selected human disorders/traits with estimated heritability.  
Traits/Disorders Heritability (%) 
Acne 81 
Age-related macular degeneration 49 - 71 
Alcoholism 50 - 60 
Alzheimer's disease 58 - 79 
Asthma 30 
Attention deficit hyperactivity disorder 70 
Autism 30 - 90 
Bipolar disorder 70 
Bladder cancer 7 - 31 
Blood pressure, diastolic 49 
Blood pressure, systolic 30 
Body mass index 23 - 51 
Bone mineral density 44 - 87 
Breast cancer 25 - 56 
Celiac disease 57 - 87 
Cervical cancer 22 
Chronic obstructive pulmonary disease 76 
Colon cancer 13 
Coronary artery disease 49 
Depression 50 
Epilepsy 70 - 88 
Eye color 98 
Heart disease 34 - 53 
Height 55 - 81 
Hypertension 30 
Leukemia 1 
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Longevity 26 
Lung cancer 8 
Nicotine dependence 60 
Obesity 70 
Ovarian cancer 40 
Parkinson's disease 25 - 30 
Periodontitis 42 
Prostate cancer 42 
Psoriasis 66 
Schizophrenia 81 
Stomach cancer 1 
Stroke 32 
Testicular cancer 25 
Thyroid cancer 53 
Type-1 diabetes 88 
Type-2 diabetes 26 
Data source: SNPpedia(http://www.snpedia.com/index.php/SNPedia). 
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Chapter 2: Application of Non-collapsing 
Methods to Gene-based Association Test 
2.1 Introduction 
Unlike GWAS which focuses on common SNPs that have relatively higher MAF, 
sequencing based association study could generate tons of rare or low frequency variants 
and traditional statistical methods often fail in association mapping due to poor statistical 
power. To address this issue, as introduced in Chapter I, one commonly utilized strategy 
is to collapse rare variants information within specific genomic regions (such as genes), 
and this ―super marker‖ will be tested statistically[20][ 21][ 22]. This strategy could 
partly solve the issue of statistical power, however, it has assumes the directions of the 
effects of DNA variants are consistent, and this assumption may not be true. Compared to 
these collapsing methods, the non-collapsing methods, which do not require the 
assumption of consistency of effects direction, may be more reasonable choices for rare 
variants based association mapping.  
In this chapter, we proposed a two-stage, gene-based method for association 
mapping of rare variants by applying four different non-collapsing algorithms using the 
whole genome sequencing dataset and simulated blood pressure phenotype of genome 
analysis workshop (GAW) 18[39]. Genetic analysis workshop provided a platform for 
developing and evaluating statistical methods to analyze population and family based 
human genetics data. It is held every other year. GAW18 focused on identification of 
genes and functional variants that influence complex phenotypes in human sequence data. 
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In this research we will first obtain significance P values by fitting a mixed effects 
model for each variant, and then apply four non-collapsing algorithms, including Fisher’s, 
gene set enrichment analysis (GSEA), sequence kernel association test (SKAT),  to 
obtain the gene-wise association P values. Collapsing (or burden) methods combine 
variant information by assuming consistent direction of effects across variants. None of 
the methods considered here adopt this assumption, although some do combine variant 
information.  
2.2 Materials and Methods 
2.2.1 Model fitting and algorithms 
A mixed linear model was fitted for each variant as described in previous 
literature [40]. The model was defined as: 
 （2.1）, 
where Y is the quantitative trait of interest (we used first-visit systolic blood 
pressure [SBP]); X is the genotype; β is the fixed effects of the genotypes; and Q 
represents the population structure variables . In this study, we chose the first 10 principal 
components from principal component analysis (PCA) for Q. ν is the fixed effects of Q; Z 
is the variable that evaluates familial relatedness (the theoretical kinship matrix was used 
for Z); and µ is the random effects coefficient for Z that corrects the polygenic impact. 
After obtaining the variant-wise P values by fitting the mixed linear model shown 
above, four non-collapsing algorithms were modified and applied to the data set to obtain 
Y X Q Z      
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the gene-wise association P values. The algorithms of the four methods are summarized 
as followed: 
1. Naïve method. The most significant variant-wise P values within a specific 
gene were chosen as the gene-wise association P values. 
2. Fisher’s method [41]. The gene-wise statistics were calculated through the 
following equation: 
      （2.2）, 
where pi is the p value for variant i, and k is the total number of variants within a 
specific gene. Because many variants are highly correlated, the basic assumption of 
independent tests for Fisher’s method is violated. Fisher’s formula may not have a 
chi-square distribution, so we assessed the significance via permutations. 
3. Simes’ method [42]. The gene-wise p value was summarized by the following 
equation: 
     （2.3）, 
where pi is the p value for variant i, and k is the total number of variants within a 
specific gene. 
4. GSEA method [43][44]. The test statistics (indicated as ES score) were 
aggregated from variant-wise p values within each gene via a Kolmogorov-Smirnov–like 
process in which running sums are accumulated. The equation is given as: 
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    （2.4） 
where N is the total number of variants, r(j) is the j
th
 largest statistic values, NH is 
the variant number of a given gene, S is any given gene, P is the parameter that gives a 
higher weight to variants with extreme statistic value, arbitrarily set to 1 in this study, and 
NR is given by: 
           （2.5） 
Statistical significance and adjustment for multiple hypothesis testing were 
assessed by a 1000 permutation based procedure. A family-wise error rate (FWER) 
procedure was used to adjust for multiple-hypothesis testing. In this study, the FWER p 
value was calculated as the fraction of all permutations whose highest statistics (or 
smallest p values) in all genes is higher than a given gene. In addition to the four 
non-collapsing algorithms introduced above, we also included two standard rare variants 
based methods: SKAT [21] and famSKAT [45] in our analysis. FamSKAT is an extended 
version of SKAT and can be utilized to analyze rare variant when family correlations are 
present. Furthermore, to evaluate the statistical power of these methods, we extracted the 
variant information related to the 22 true-positive genes located on chromosome 3 and 
analyzed these data for all 200 simulated phenotype replicates. 
2.2.2 Data and computation 
We only analyzed one phenotype replicate and sequencing data of chromosome 3 
due to the huge computational burden. The sequencing data were annotated by 
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ANNOVAR [46]. Intergenic variants (variants at least 1 kilobase [kb] away from any 
known gene regions) were excluded, but variants that can be mapped to regulatory 
regions (ORegAnno) were kept [47].  
To preserve the familial structure, a permutation-of-residuals procedure was 
applied [48]. First, we fitted a mixed effects linear model on the phenotypic data with all 
the covariates in the model (except for genotype term) and preserved the residuals for 
these models. Second, we shuffled the residuals (rather than the phenotypic data used in 
an ordinary permutation procedure) and randomly assigned them to each subject and 
generated 1000 phenotypic data replicates. And third, we obtained the permuted statistics 
and p values by fitting a univariate linear model with genotype as the only predictor of 
the residuals. This method may introduce potential bias to the permuted statistics and p 
values comparing to directly fitting the full model. To quantify this potential bias, we 
randomly chose 1429 variants and calculated the percentage difference of the −log10 
scaled p values obtained from directly fitting a full model and from the two-step 
permutation procedure proposed above. The results of the permutation bias analysis 
showed that the percentage difference was only approximately 10%, and the correlation 
coefficient of variant-wise statistics was 0.9959. These results indicate that the effects of 
this bias are limited. 
Genotypes were coded in dominant model. That is, the genotypes with 1 or 2 
minor alleles were coded as 1, while genotypes with 2 major alleles were assigned 0. 
Variants with minor allele frequency >0.3 in genome-wide association data set were 
selected for PCA. We used Eigenstrat 3.0 for this analysis [49]. The R package kinship2 
(http://cran.r-project.org/web/packages/kinship2/index.html) was used to calculate the 
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kinship coefficient matrix for our data set. The R package coxme 
(http://cran.r-project.org/web/packages/coxme/index.html) was implemented for fitting 
the mixed linear model. The R package SKAT 
(http://cran.r-project.org/web/packages/SKAT/index.html) was implemented for rare 
variant analysis with SKAT. The R source code for famSKAT was downloaded 
(http://www.bumc.bu.edu/linga/research/publications/famskat/) and implemented for rare 
variant analysis. Receiver operating characteristic (ROC) curves were made and 
compared among the four algorithms and two standard methods. 
2.3 Results 
The data consisted of 1,237 genes with 87,190 variants that passed the annotation 
criteria were extracted from the sequencing data set of chromosome 3 for 849 subjects. 
After fitting the mixed linear model, the Q-Q plot and histogram of p values of these 
87,190 variants is shown in figure 2.1. Data for the 22 true positive (true answer) genes 
with 1,098 variants were extracted and used for analysis with 200 simulated phenotype 
replicates. The statistical power information for all the six methods was summarized and 
is presented in table 2.1. From the power analysis results, we see that the gene MAP4 was 
successfully identified to be significant for all simulated 200 replicates.  All six methods 
achieved 100% power for this gene. For the rest 21 genes, the largest power was 27.5%, 
which was achieved by SKAT for LOC152217. 
To compare the four non-collapsing methods and the two standard methods, ROC 
curves based on these six methods were constructed and shown in figure 2.2. From this 
fugure we noted that, overall, the Simes’ method performed a little better compared to the 
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other five methods, and that GSEA, SKAT and famSKAT did not perform as well as 
Simes’ method. The other two methods were slightly better than GSEA, SKAT and 
famSKAT method. However, when we limited the false positive rate to be smaller than 
0.1 as shown in the right hand plot of figure 2.2 (in practice, only a high true positive rate 
with a low false positive rate is of interest), we see that Fisher’s method and famSKAT 
performed better than other methods at the low false positive rate range. They both 
capture around 15% of the causal genes (true positives) with a cost of only 5% false 
positive signals. However, we did not test the significance of the ROC curves, so that all 
these observed differences could just be noise.  
2.4 Discussion and Conclusion 
MAP4 was identified to be the causal gene with 100% statistical power. This 
result is reasonable since, according to the ―answer sheet‖ of GAW18, MAP4 contains 
the most ―causal variants‖ and these variants have a relatively larger effect size 
comparing to the variants within other genes.  However, this result was obtained when 
we only analyzed the 22 ―true answer‖ genes. For a genome-scale analysis, the 
significant signals may be missed due to correction for multiple comparisons. We have 
also analyzed the whole genotypic dataset of chromosome 3 with simulated phenotypic 
replicate #1(including 1,237 genes and 87,190 variants). The result indicated that only 
naïve method and the two standard methods identified gene MAP4 to be significant.  
The non-collapsing methods introduced in this paper have been broadly utilized in 
testing the significance of biological pathways in GWAS datasets. When we substitute 
the term ―pathway‖ in these non-collapsing algorithms for the term ―gene‖ in sequencing 
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analysis and ―gene‖ for ―variants‖, we can apply these non-collapsing algorithms to 
gene-based association detection through modifications. An obvious advantage of 
aggregating p values (or statistics) by applying non-collapsing algorithms compared to 
ordinary variants collapsing methods is that it is a method free of the assumption that all 
the causal variants from a gene have effects in the same direction. This assumption may 
not be held in many scenarios even though it is the assumed in many existing rare 
variants association mapping procedures. 
In this study, we utilized the residuals-of-permutation procedure to deal with our 
familial based data. Conducting a permutation on family data has been a challenge in 
statistical genetics research. Ordinary permutation procedures have been mostly utilized 
in case-control data, which simply shuffle the phenotypic data and randomly assigns 
them to each subject, thus cannot be directly applied to family data because it destroys 
the family structure. In our research, instead of shuffling the phenotypic data, we shuffled 
the residuals obtained from fitting a linear mixed effects model without genotype. These 
residuals have already accounted familial relatedness in the model fitting step and 
therefore our permutation procedure preserved the familial structure.  
Several previous researchers have already applied the non-collapsing methods 
proposed in our research to conduct gene-based analysis [50][51]. However, these 
previous works have mainly focused on common variants in GWAS dataset. As an 
attempt to apply these non-collapsing algorithms to gene-based association tests using 
sequencing data, we have demonstrated some potentially promising aspects of this 
approach. However, several problems remain unaddressed. One important issue is the 
computational intensity. In this study, we have utilized a multi-processor-computing 
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server with 23×2.8 GHz CPU and 64GB memory in total. The most time consuming part 
of our analysis is the permutation-of-residuals process and linear model fitting of the 
permuted datasets. We have paralleled this process into 20 jobs, but it still takes around 
30 hours to complete (this is only the work done for one chromosome). Compared to the 
permutation process, the p value combination step can be completed much faster (~30 
minutes). Since a lot of the non-collapsing algorithms require permutation procedures to 
create null distribution of the statistics, it is somewhat difficult to implement them on 
genome-wide scale dataset. In addition, many non-collapsing algorithms cannot be 
utilized for a gene-based association test directly without proper modifications. The 
choice of parameters in non-collapsing algorithm for rare variant association detection is 
more an art than a science. Finally, adjustment for multiple hypothesis testing is another 
important issue that needs to be addressed. Our results indicate that the FWER method is 
too conservative. For the future work, hierarchical modeling combined with MCMC may 
provide better solution to the multiple hypothesis testing problems [52].  
To conclude, in this study, we showed that the statistical efficiency of several 
sequencing data based methods were not very promising, although some of them were 
commonly utilized in sequencing data analyzes as standard methods. Further 
investigation is needed to explore the potential statistical properties of these approaches. 
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2.5 Figures 
 
Figure 2.1 Q-Q plot and histogram for the mixed effects model. Q-Q plot (left) of –log10 
scaled p-values and histogram (right) for the mixed effects model based on 1,237 genes 
(87,190 variants) from 849 subjects. In Q-Q plot, black line, expected; blue dots, 
observed. 
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Figure 2.2 ROC curves for four non-collapsing algorithms and two standard methods. 
ROC curves for four different pathway algorithms based on 1,237 genes from 849 
subjects on trait SBP (first visit). In the left plot FPR ranges from 0 to 1. In the right plot 
FPR is scaled to be less than 0.1 since only the true positive rate (TPR) with a low FPR is 
of interest. Black curve, naïve method; blue curve, Fisher’s method; red curve, Simes’ 
method; green curve, GSEA method; purple curve, SKAT; yellow curve, famSKAT. 
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2.6 Tables 
Table 2.1 Comparison of the statistical power of the four non-collapsing and two standard methods.  
CHR Gene Power of Methods 
Naïve Method Fisher’s Method Simes’ Method GSEA Method SKAT FamSKAT 
3 ABTB1 0.015 0.18 0.025 0 0.075 0.01 
3 ARHGEF3 0 0 0 0.035 0.005 0.005 
3 B4GALT4 0.015 0 0.015 0.035 0.01 0.015 
3 BTD 0 0 0 0.015 0 0 
3 CXCR6 0 0 0 0.085 0 0 
3 DNASE1L3 0.005 0.005 0.005 0.005 0.04 0.01 
3 FBLN2 0.005 0 0 0.035 0 0 
3 FLNB 0.01 0.015 0 0.03 0 0 
3 LOC152217 0.09 0.145 0.135 0 0.275 0.04 
3 MAP4 1 1 1 1 1 1 
3 NMNAT3 0.005 0.04 0.005 0 0 0 
3 PAK2 0.07 0 0.05 0 0 0 
3 PDCD6IP 0.005 0 0.005 0.005 0.04 0.03 
3 PPP2R3A 0.045 0.01 0.02 0 0.005 0.005 
3 PTPLB 0 0 0 0.02 0.005 0 
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3 SCAP 0.025 0.005 0.04 0 0.045 0.065 
3 SEMA3F 0 0 0 0 0 0 
3 SENP5 0 0.02 0.01 0.045 0.01 0.005 
3 SUMF1 0.085 0.005 0.06 0.01 0.015 0.005 
3 TFDP2 0 0 0 0.035 0 0 
3 TUSC2 0.005 0 0.055 0 0.02 0 
3 ZBTB38 0.01 0.005 0.01 0.02 0.04 0 
Power is calculated based on the analysis of the 200 simulated phenotypic replicates. The largest power for each gene is highlighted in 
bold. 
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Chapter 3: Family-based Whole Exome 
Sequencing Study for Bipolar Disorder 
3.1 Introduction 
3.1.1 Clinical and epidemiological characteristic of bipolar disorder 
Bipolar disorder (BPD) is a mental illness with lifetime prevalence of about 1% 
[53]. BPD is characterized by periods of elevated mood (manic/hypomanic episodes) and 
periods of depression (depressive episodes) [54]. Currently, there is no cure for BPD, and 
medications and therapies are used to treat the symptoms. Patients with BPD and their 
families experience significant losses in functional status and quality of life, placing 
untoward stress on personal relationships. In addition, BPD is one of the most expensive 
mental health care diagnosis, both for patients with the illness and for their health 
insurance plans [55], and that in turn adds a financial burden on the patients’ families, as 
well as on society as a whole. Biomedical and etiological studies on the onset and 
development of BPD can throw light on new drug discovery and therapy development. 
3.1.2 Gene association mapping of bipolar disorder: a brief review 
The etiology of BPD is not clearly understood but extensive research has 
indicated that both genetic and environmental factors play a role [56]. Familial clustering 
studies have identified a ten-fold higher risk of BPD in people who have affected first 
degree relatives when compared to the general population [56]. The heritability of overall 
bipolar spectrum disorders is estimated to be 0.71[57]. More than 40 linkage scans for 
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BPD have been published and implicate many areas of the genome, although several 
studies have inconsistent results [56]. Genome-wide association studies (GWAS) have 
identified several susceptibility loci including markers near PALB2 [58], DGKH [59], 
ANK3& CACNA1C [60], 3p21 [61], NCAN [62], ODZ4 [63], TRANK1& LMAN2L [64], 
ADCY2&6q16 [65], and SESTD1 [66]. Nevertheless, despite these findings, a recent 
study has estimated the SNP heritability (the proportion of variation in disease liability 
that is captured in GWAS by considering all SNPs simultaneously) was ~0.4 for BPD 
[10]. This indicates that further research is needed to unravel the genetic etiology for 
BPD.  
The traditional microarray chip technology based GWAS focuses on common 
variants (genetic variants that have minor allele frequency at 5% or higher), and 
selectively omits the rare variants and structural variants such as short insertion and 
deletions (indels) due to technological problems [67]. The recent development of 
―next-generation‖ sequencing technology has enabled researchers to investigate these 
variants which are not covered in GWAS at a relatively lower genotyping cost [68]. 
Exome sequencing, which sequences the exons of protein coding genes in the genome, is 
considered to be a powerful tool in genetic association research [69]. By focusing only on 
the region of exons, exome sequencing only sequences around 1% of the human genome 
(far less than whole genome sequencing) while investigating genomic regions of 
functional significance. A recent research project focusing on lithium-responsive bipolar 
disorder has identified several rare susceptibility variants by exome sequencing analysis 
based on 36 familial samples [70]. This result indicates that exome sequencing 
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technology combined with proper study design is a promising method for association 
mapping.  
In this chapter, we have recruited six related BPD cases from a single BPD 
extended family. The rationale is that a single variant is segregating in this large, unusual 
family and that this approach will minimize genetic heterogeneity by restricting analysis 
to a single family. We have performed whole exome sequencing on the six BPD cases, 
and examined the DNA variants that are shared among all these six cases. Additionally, 
we have also performed a genome-wide high density linkage analysis based on common 
SNP data. The linkage peak region has further narrowed down the potential susceptibility 
variants and genes for BPD. 
3.2 Materials and Methods 
3.2.1 Study subjects 
The BPD family was selected via a history of multiple relatives with BPD. An 
index case was recruited from department of psychiatry at Barnes-Jewish Hospital. 
Relatives were diagnosed via diagnostic interview (SADS-L) and two independent senior 
psychiatrists gave best estimated diagnosis made through consensus. Signed consent 
forms were obtained from all the recruited members. This study was approved by IRB of 
Washington University in St. Louis. The pedigree structure of the family recruited in this 
study was shown below (figure 3.1). Six subjects with BPD were included in this study. 
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3.2.2 Experimental Methods 
Genomic DNA was isolated from the peripheral blood leukocytes and the DNA 
was stored at −80 °C for genotyping. The microarray genotyping was done by Illumina 
OmniExpress. We applied quality control process to remove singletons and SNPs with 
missing rate higher than 10%. The whole-exome sequencing was carried out using 
Agilent SureSelect All Exon 50Mb Target Enrichment kit and on the SOLiD System by 
EdgeBio.  The average read depth for the six bipolar subjects were 57x. For the 
exome-seq data, the alignment was done using novoalignCS (V1.01.15) by EdgeBio, and 
the data were recalled with HaplotypeCaller (GATK v3.3) [71]. The QC was done by 
GATK¹s VQSR. 
3.2.3 Statistical methods 
We implemented parametric linkage analysis based on the software Merlin [72] to 
identify potential linkage peak regions with the pedigree data. The allele frequency data 
were extracted from Hapmap 2 CEU samples. SLINK [73] was used to simulate the 
linage analysis to obtain a LOD score threshold with acceptable statistical power. The 
potential effects of exonic SNVs were predicted using SIFT [74] and Polyphen2 [75].  
The redundancy of the microarray SNP chip panel enables us to implement a 
10-set replicate analysis strategy in order to reduce the number of potential false positive 
signals obtained from the linkage analysis. We 1) randomly selected 10 sets of SNPs with 
considerations of minor allele frequency (MAF> 0.3), Linkage disequilibrium (LD) 
structure (to account for LD) and their genomic coverage (each SNPs set contains around 
10,000 markers); 2) conducted linkage analysis with each of these 10 replicated SNP sets 
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independently; and 3) identified the peak regions that are repetitively identified in all of 
the ten rounds of analysis. To account for the potential impact of LD on linkage signals, 
we only chose one SNP from each LD block which was constructed based on the 
Hapmap European population data. The LD block was estimated using Plink [76]. 
We implemented the Perl based software ANNOVAR[46] to annotate the exome 
sequencing data. To investigate the potential susceptibility variants/genes within this 
large family, we extracted variants that 1) pass the quality control criteria specified in 
GATK software; 2) are under one of the linkage peak regions; 3) located within genetic 
region with functional significance (splicing site variants, non-synonymous SNVs, stop 
gain SNVs,  frameshift indels, or non-frameshift indels within exonic regions) and 4) 
Only variants that were not recorded in 1000 genome database or variants with recorded 
MAF < 0.05 were included.  We also incorporated our filtering results with R package 
RVsharing [77] to have a statistical estimate of our observed excess sharing among all the 
related BPD cases of those candidate variants.  
3.3 Results 
3.3.1 Results of linkage analysis  
Simulation of the linkage analysis with SLINK showed that a LOD threshold 2.0 
will only achieve 22% statistical power. To increase statistical power, we chose 1.8 as the 
LOD threshold with the cost of increasing the false positive rate. To control the number 
of potential false positive linkage signals, we implemented a 10-replicate linkage analysis 
strategy. Genotypes data were released for 733,202 SNPs with our Illumina microarray 
chip and 537,258 were left after quality control. The redundancy of these markers 
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enabled us to implement a 10-replicate analysis strategy to reduce the number of the 
potential false positive linkage signals. This marker sets selection and analysis 
implementation was as indicated above.  
The linkage analysis results of 10 replicate SNP sets are shown in table 1. As 
shown in table 1, four peak regions in total were identified from the linkage analysis. 
They are 5q33.1- 5q 33.3, 5q35.1-5q35.2, 10q21.1-10q21.2 and 10q23.1-10q23.33. Two 
of these 4 linkage peaks, 5q33.1- 5q 33.3 and 5q35.1-5q35.2 (figure 3.2) were only 
identified 3 and 1 times, respectively. This indicates that these two linkage peak signals 
may be false positive signals. The two consecutive peak regions on chromosome 10, 
10q21.1-10q21.2 and 10q23.1-10q23.33 (10q22.3-10q23.33) were identified multiple 
times in the 10 replicate sets and 10q23.1-10q23.33 (10q22.3-10q23.33) was identified 
repetitively in all of the 10 replicate SNP sets. This result indicates that the chance that 
this peak region is a false positive signal is very low (figure 3.3).  Here we provide a 
brief estimation for the false positive rate of this peak region. The LOD threshold we 
used here is 1.8, and this is approximately equal to p value <0.002 [78]. Although we 
tested around 10,000 SNPs, considering the potential LD among SNPs, the independent 
number of tests might be around 400 (this is a reasonable estimate because 400 is the 
number of tests when using microsatellite markers for linkage analysis). Therefore, the 
false positive rate for each replicate is around 0.55 (1-0.998
400
).  For a genomic region 
that is proved to be significant in all of the ten replicates, its false positive rate can be as 
low as 0.0025 (0.55
10
). Therefore we concentrated those variants under this peak region 
(10q23.1-10q23.33) on chromosome 10. We have summarized the results of linkage 
analyses of each marker set in table 3.1. 
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3.3.2 Results of variants filtering 
Genotypic data were released for 140,814 variants (table 3.2). Among the 140,814 
variants, 114,432 (81.26%) variants passed the quality control specified in GATK 
software. Within these high quality variant calls, 444 variants were located under the 
linkage peak region of chromosome 10. The number of variants was reduced to 60 if we 
only considered those variants with potential functional significance. Among these 60 
variants, a total of 15 variants were not recorded in 1000 genome database or were rare 
variants with MAF less than 0.05 according to 1000 genome data in Caucasian 
population. Nine out of these 15 variants were only identified in one of six bipolar 
subjects sequenced, and 6 variants were shared by 2, 3 or 4 individuals. We have 
summarized the information of these 6 variants in table 3.3. Tests of RVSharing indicated 
that three out of these six variants (shared among 3 or 4 patients) were statistically 
significant with P value <0.008 (0.05/6). The other three variants that were shared among 
two patients had a P value of 0.0695. These 6 variants come from 5 genes including 
DYDC2, GHITM, MINPP1, CDHR1 and GRID1. Two SNVs located in the genes 
CDHR1 and GRID1 were predicted to be ―damaging‖ or ―possibly damaging‖ by SIFT 
and Polyphen-2.   
3.4 Discussion and Conclusion 
Our aim was to identify potential susceptibility variants that contribute to the risk 
of BPD. In order to minimize genetic heterogeneity, we restricted analysis to a single 
large family in which several distantly-related individuals suffer from BPD. If a single 
variant affecting risk for BPD is segregating in this multiply affected family, this 
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approach should identify the variant within the larger set of segregating variants, 
nominating candidate genes for future studies.  
We narrowed the targeted genomic region down to a ~15 MB region by restricting 
the analysis to a linkage peak identified on chromosome 10. This region (10q22) has been 
previously reported to be linked with BPD in a large scale linkage study by Fallin et al 
[79].  After filtering for minor allele frequency, sharing among affected relatives, and 
functional significance of the potential susceptibility variants, we identified a list of 6 
variants within 5 genes. A total of 3 variants in 2 genes, GRID1 and CDHR1, were 
identified in 2 of the 6 BPD cases. The two cases that shared these 3 variants are also first 
cousins within this four generation pedigree (individuals #142 and #5 from (figure 3.1).  
GRID1 encodes a subunit of glutamate receptor channels. These channels mediate most 
of the fast excitatory synaptic transmission in the central nervous system and play key 
roles in synaptic plasticity [80]. GRID1 has been widely investigated in multiple 
psychiatric disorders and brain related traits [81][82][83][84]. It was first reported by 
Fallin et al. that GRID1 was significantly associated with schizophrenia and associated 
with BPD with suggestive significance among Ashkenazi Jewish case-parent trios [81].  
A study of mice in which the GRID1 homologue, GluD1, was knocked out reported that 
the mice were hyperactive, manifested lower anxiety-like and depression-like behavior, 
and robust aggression [85].  The two rare GRID1 variants we report here (rs2306265 
and rs3812645) represent the first evidence that rare variants in GRID1 may contribute to 
BPD.  
The other gene with a shared rare variant, CDHR1, belongs to the cadherin 
superfamily of calcium-dependent cell adhesion molecules. Its encoded protein is a 
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photoreceptor-specific cadherin that plays a role in outer segment disc morphogenesis 
[86]. Mutations in this gene have been associated with recessive retinal degeneration [87] 
and autosomal recessive cone-rod dystrophy [88]. However, no previous study has linked 
this gene to any psychiatric disorders. We also identified 3 interesting variants in DYDC2, 
GHITM and MINPP1. These variants were predicted to be ―benign‖ or ―tolerated‖ and 
might not affect the protein structure. However, all of these variants were shared by 3 or 
4 BPD cases in this pedigree, and their sharing patterns were significant after Bonferroni 
correction using the RVsharing algorithm.  
We note that, given our sample size, these P values can only be used as a 
suggestive guidance when prioritizing variants for further study. One major strength of 
our study is that as an exome sequencing based study, we can examine both common and 
rare variants. Previous association studies on BPD mainly focus on common SNPs while 
ignoring most of the low frequency and rare variants. Restricting to common SNP, may 
hinder the ability to find susceptibility variants or genes. In our study, we considered both 
rare and common functional variants via exome sequencing technology. In addition, an 
advantage of our family based study design is that rare variants that segregate with 
reasonably high penetrance in an extended pedigree can provide a linkage signal helpful 
in identifying the susceptibility genes.  
There are also several limitations of our study. A main limitation is that we lack 
familial controls. The variant sharing we utilized as a filtering strategy in our study might 
generate some false positive signals due to relatives sharing neutral DNA variations. 
Having exome sequencing data from several healthy family members of this pedigree 
might further narrow down our candidate gene list. It is still too early for us to make any 
40 
conclusion on the potential role played by these candidate genes in the onset and 
development of BPD. Limited by our sample type and study design, further research is 
needed to replicate our finding in unrelated individuals. More research is needed to reveal 
the potential relationship of our candidate gene list and biological mechanisms of BPD. 
In summary, our study identified a list of 5 potential candidate genes for BPD 
based on exome sequencing in a large bipolar disorder pedigree. Among these 5 genes, 
GRID1 has been reported to be associated with several psychiatric and brain related traits 
in common SNP-based studies. Our results provide some evidence linking rare variation 
in GRID1 with BPD.  These findings suggest a potential role for these genes in the risk 
for BPD, but require replication in large, independent studies.  
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3.5 Figures 
 
Figure 3.1 Pedigree structure of the BPD family sequenced in this study. Blood samples 
of the 6 BPD cases at the bottom of the pedigree were collected.     
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Figure 3.2 Significant peak regions identified on chromosome 5 in three sets of linkage 
analysis. a. Linkage results for chromosome 5 using SNP set #4 with 10,058 SNPs; b. 
Linkage results for chromosome 5 using SNP set #6 with 9,715 SNPs; c. Linkage results 
for chromosome 5 using SNP set #8 with 10,402 SNPs. Two peak regions 5q33.1- 5q 
33.3 and 5q35.1-5q35.2 were identified 3 and 1 times respectively. The LOD threshold 
was indicated in dotted line.  
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Figure 3.3 Significant peak regions identified on chromosome 10 in all the ten sets of 
linkage analysis. a. Linkage results for chromosome 10 using SNP set #1 with 10,396 
SNPs; b. Linkage results for chromosome 10 using SNP set #2 with 9,648 SNPs; c. 
Linkage results for chromosome 10 using SNP set #3 with 9,963 SNPs; d. Linkage results 
for chromosome 10 using SNP set #4 with 10,058 SNPs; e. Linkage results for 
chromosome 10 using SNP set #5 with 10,407 SNPs; f. Linkage results for chromosome 
10 using SNP set #6 with 9,715 SNPs; g. Linkage results for chromosome 10 using SNP 
set #7 with 10,418 SNPs; h. Linkage results for chromosome 10 using SNP set #8 with 
10,402 SNPs; i. Linkage results for chromosome 10 using SNP set #9 with 10,236 SNPs; 
j. Linkage results for chromosome 10 using SNP set #10 with 10,402 SNPs. Chromosome 
region 10q21.1-10q21.2 and 10q23.1-10q23.33 (10q22.3-10q23.33) were identified 
multiple times in the 10 replicate sets and 10q23.1-10q23.33 (10q22.3-10q23.33) was 
identified repetitively in all of the 10 replicate sets. The LOD threshold was indicated in 
dotted line. 
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3.6 Tables 
Table 3.1 Linkage analysis results of the ten replicate sets.  
Set # of markers Chromosome Regions  LOD 
1 10,396 10q22.3-10q23.33  1.92 
2 9,648 10q21.1-10q21.2  1.91 
    10q22.3-10q23.33  1.92 
3 9,963 10q21.1-10q21.3  1.91 
  
10q22.3-10q23.33  1.93 
4 10,058 5q33.1-5q33.2  1.88 
  
10q21.1-q22.3  1.91 
    10q23.1-10q23.33  1.92 
5 10,407 10q21.1-10q21.2  1.91 
  
10q23.1-10q23.33  1.92 
6 9,715 5q33.1- 5q 33.3  1.9 
  
 5q35.1-5q35.2  2.77 
    10q23.1-10q23.33  1.92 
7 10,418 10q21.1-10q21.2  1.91 
  
10q23.1-10q23.33  1.92 
8 10,402 5q33.1- 5q 33.2  1.9 
  
10q21.1-10q21.2  1.91 
    10q23.1-10q23.33  1.92 
9 10,236 10q21.1-10q21.2  1.87 
  
10q23.1-10q23.33  1.92 
10 10,402 10q21.1-10q21.2  1.9 
    10q23.1-10q23.33  1.92 
The most significant linkage peak region was found on chromosome region 
10q22.3-10q23.33 with LOD score of 1.926. The LOD threshold is 1.8.We have 
highlighted the 10q23.1-10q23.33 which were identified to be significant in all ten SNP 
replicates. 
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Table 3.2 Filtering procedure applied to the exome sequencing data from 6 BPD relative 
cases.  
Filtering Procedure Number of Variants pass QC (%) 
Genotype calls released 140,814 (100) 
Quality Control 114,432 (81.26) 
Linkage Peak Region 444 (0.32) 
Variants with functional significance 60 (0.04) 
Novel variants or variants with MAF less than 0.05 15 (0.01) 
The number of variants is reduced to 15 from the 140,814 released by exome sequencing 
by applying various filtering strategies.   
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Table 3.3 Summary information for 6 genetic variants identified after applying the filtering strategy. 
CHR SNP Position Ref Alt Gene Function AAChange SIFT* Polyphen2** Sharing P*** 
10 rs36027713 82126541 C G DYDC2 nonsynonymous SNV p.P123R T B 4 0.0003 
10 - 85902497 A T GHITM nonsynonymous SNV p.E72D T B 4 0.0003 
10 rs45584033 85974231 C T CDHR1 nonsynonymous SNV p.P812S D D 2 0.0695 
10 rs2306265 87484382 C T GRID1 nonsynonymous SNV p.V529I D D 2 0.0695 
10 rs3812645 87489317 T C GRID1 nonsynonymous SNV p.M430V T B 2 0.0695 
10 - 89280872 C T MINPP1 nonsynonymous SNV p.T137I T B 3 0.003 
* SIFT prediction. T stands for tolerated and D stands for damaging. 
** Polyphen2 prediction. B stands for benign, P stands for possibly damaging, and D stands for probably damaging.  
*** P values here stands for the probability of observing the sharing pattern in our pedigree. Significant variants after applying 
Bonferroni correction were shown in bold.
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Chapter 4: Targeted Sequencing 
Identifies Genetic Polymorphisms of 
Flavin-containing Monooxygenase 
Genes Contributing to Susceptibility of 
Nicotine Dependence in European and 
African Americans 
4.1 Introduction 
4.1.1 Clinical and epidemiological characteristic of nicotine dependence 
Smoking is a leading cause of preventable death, causing about 5 million 
premature deaths worldwide each year, and current trends show that tobacco use will 
cause more than 8 million deaths annually by 2030 [89]. Strong evidence connects 
cigarette smoking and lung cancer [90][91][92], and according to the data from 
American cancer society, lung cancer causes the most death each year compared to 
other cancers [93]. In addition, cigarette smoking is also the principal environmental 
risk factor for developing chronic obstructive pulmonary disease (COPD), a disease 
characterized by chronically poor airflow [94][95][96] . Therefore, understanding the 
underlying biological mechanisms of nicotine dependence will still have huge public 
health significance in the future. 
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4.1.2 Gene association mapping of nicotine dependence: a brief review 
Early studies based on samples of twins have linked the lifetime smoking 
practices to genetic predisposition [97]. A meta-analysis of the data from five studies, 
each involving more than 1,000 twin pairs, showed an estimated heritability of 60% 
for the propensity to smoke [98]. The followed linkage and gene association mapping 
studies have identified several susceptible loci, including genes encoding dopamine 
transporter/receptors [99][100][101], cholinergic receptors [102][103][104][105] , 
taste receptor [106] , serotonin receptor [107][108] and gamma-aminobutyric acid 
type B receptor [109], that are associated with nicotine dependence. The breakthrough 
of microarray technology at the end of 20
th
 century enabled the ―unbiased‖ 
association mapping analysis in the whole human genome. Genome-wide association 
study (GWAS), which scans the whole genome by capturing the information of 
common SNPs, has been proved informative for nicotine dependence 
[110][111][112][113], and greatly accelerates the progress of this gene hunting 
process.  Nevertheless, GWAS only focuses on a set of pre-selected, generally 
common SNPs, and tends to omit the rare variants and structural variants such as 
short insertion and deletions (indels). The recent development of ―next-generation‖ 
sequencing technology has enabled researchers to investigate these variants which are 
not covered in GWAS at a relatively lower genotyping cost [114][115][116]. A recent 
published study focusing on targeted sequencing data of CHRNA5 has identified 
several novel rare and low frequency coding variants that contributed to nicotine 
dependence [117].  
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Three protein families are involved in nicotine pharmacokinetics: liver 
cytochrome P450 enzymes (CYPs), flavin-containing monooxygenases (FMOs) and 
uridinediphosphate glucuronosyltransferase enzymes (UGTs) [118]. The 
flavin-containing monooxygenase (FMO) protein family consists of a group of 
enzymes that metabolise drugs and xenobiotics [119]. Five forms of FMOs are found 
in human and have been designated FMO1-FMO5 [119]. Among these FMO genes, 
part of nicotine inhaled during smoking can be broken down to N′-oxide by 
flavin-containing monooxygenase 3 (encoded by FMO3) [118]. Hinrichs et al. has 
identified significant association between SNPs of FMO1 and nicotine dependence 
[120]. Although a recent study has shown that common polymorphisms in FMO3 can 
influence nicotine clearance [118], no study has provided direct evidence of the 
association between FMO3 polymorphisms and nicotine dependence.   
In this chapter, we investigated the potential of FMO genes to confer risk of 
nicotine dependence via deep targeted sequencing in 2,820 study subjects (1,432 
European and 1,388 African Americans) comprising of 1,583nicotine dependents and 
1,237controls. Specifically, we focused on the two genomic segments including 
FMO1, FMO3 (protein coding genes for flavin-containing monooxygenase 1 and 3) 
and FMO6P (pseudo gene), and aimed to investigate the potential association between 
FMO genes and nicotine dependence. Via implementing targeted sequencing, we are 
interested to figure out that whether rare variants contribute to the association signal 
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derived from common variants. In addition, comparisons were made between the 
association results based on European Americans and African Americans.   
4.2 Materials and Methods 
4.2.1 Study subjects 
This research was reviewed and approved by the Institutional Review Board at 
Washington University in Saint Louis. All the study subjects provided informed 
consent. Study subjects were recruited from Collaborative Genetics Study of Nicotine 
Dependence (COGEND) and the Genetic Study of Nicotine Dependence in African 
Americans (AAND) [110][104]. A total of 2,820 individuals comprising of 1,432 
European and 1,388 African Americans were examined in our study. We assessed the 
study subjects’ smoking behavior using Fagerström test for nicotine dependence 
(FTND) [121]. The nicotine dependence patients were defined as current smokers 
with FTND score equal or greater than 4, and controls were defined as having FTND 
score of 0 or 1 and have smoked at least 100 cigarettes in their lifetime (Table 4.1). 
4.2.2 Targeted sequencing of FMO1 and FMO3 
DNA samples were extracted from blood with Puragene. Targeted sequencings 
on two 100kb regions of FMO1 and FMO3 were performed at the Center for Inherited 
Disease Research (CIDR). These genomic regions also contain part of gene FMO4 
and a whole psedogene FMO6P. The quality control was implemented in samples and 
variants level respectively. The mean on-target coverage was 180x for each 
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sequencing experiment and greater than 96% of on-target bases had a depth greater 
than 20x.  
4.2.4 Quality control measures 
Data quality was systematically evaluated using a robust alignment and variant 
calling workflow implemented by CIDR (http://www.cidr.jhmi.edu/index.html). Over 
100 quality control metrics were evaluated in real time to quickly identify potential 
errors and implement fixes throughout the sequencing process. Briefly, sample quality 
controls were conducted based on batch effects, discordance with array data, alternate 
callsets, relatedness and some research specific criteria. Strategies used for variant 
quality control includes VQSR, duplicate sample discordance, Mendelian errors, 
Hardy-Weinberg equilibrium (HWE), sequence context, locus report by gene and 
genotype missing rate. All variants passed the Variant Quality Score Recalibration 
with a mean quality score of 99, mean depth of 122 with no missing calls, no 
Mendelian errors and zero discordances between duplicate samples. Importantly, all 
the rare variants were then manually evaluated by the Quality Assurance/Quality 
Control analysis team.  
4.2.3 Statistical methods and bioinformatics analysis 
A total of 1,432 European and 1,388 African Americans with targeted 
sequencing of FMO1 and FMO3 were examined. General data analyses were 
performed by R (R i386 3.2.1) [122]. To quantify the potential population 
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stratification, we conducted principal component analysis (PCA) in the combined 
sample (115,338 markers), as well as separately in the European American sample 
(154,049 markers) and African American sample (218,399 markers), using a previous 
collected genome-wide array dataset containing 950,847 SNPs [123]. Sequencing data 
were annotated by sequencing data annotation software ANNOVAR [46]. After 
variant level quality control, 5,105, 2,600 and 3,817 variants located within the two 
targeted genomic regions (FMO1/FMO3) were extracted from combined, European 
and African American sample set, respectively.  
Variants satisfying the following criteria were utilized in variant level analysis: 
1) variants with MAF > 0.05 and 2) located within targeted gene regions or the 
linkage disequilibrium (LD) blocks that are (partly) overlapped with the targeted gene 
regions (detailed definition of blocks is given below). The association analysis was 
conducted by fitting logistic regression model. The genotypic data were coded in 
additive model. This analysis was performed in combined, European American, and 
African American individuals separately (for combined subjects, we tested a union of 
SNPs sets selected based on European and African American subjects). Gender and 
age were included as covariates in all the three analyses. The first two principal 
components based on the three sample sets were also utilized as covariates accounting 
for the potential population stratification when fitting the logistic models. To address 
the multiple comparison problem, we implemented Bonferroni correction. The 
number of tests was calculated in the following way: 
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                  （4.1）, 
where for each dataset, n1 stands for the number of LD blocks generated by 
this dataset and n2 is the number of variants that do not belong to any LD blocks. In 
addition to testing associations for single variants, we also conducted haplotype based 
analysis with combination of multiple variants in European and African American 
datasets, respectively. LD blocks were constructed using the default algorithm taken 
from Gabriel et al [124]. 95% confidence bounds on D’ are generated and each 
comparison is called "strong LD" when the confidence bounds have upper bound ≥ 
0.98 and lower bound ≥ 0.7, and a block is created if 95% of informative comparisons 
are "strong LD". Variant level association analysis and LD construction and haplotype 
analyses were conducted using Plink [76].  
Variants then were classified into two categories for the gene level analysis 
(mostly rare variants). The two categories are: 1) gene-region variants set, that is the 
variants located within the gene region, and 2) functional-region variants (variants 
located within regions with significant functional significance, including exonic 
regions, 3’/5’ UTR, smaller comparing to gene-region set).  For these two variants 
sets, analysis was performed on variants with MAF less than 0.01, and 0.05. Both 
SKAT and weighted burden test [125] were utilized for the gene level analysis. Same 
as the variant level analysis, we also conducted this analysis in combined, European 
and African American individuals separately. Gender, age and first two PCs based on 
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the three sample sets were also included as covariates. LocusZoom was utilized to 
make regional association plots [126].  
We examined the targeted SNPs and/or genes using several bioinformatics 
tools and databases.  We utilized the protein-protein interaction database STRING 
(http://string-db.org/) [127] to explore the potential interactions of our targeted genes. 
The Regulome DB (http://regulomedb.org/) [128] was used to predict the potential 
functional consequences the identified risk SNPs. This database is a web based 
bioinformatics tool integrated with multiple types of data (including ChIP-seq, 
DNase-seq, and eQTLs etc.) from the Encyclopedia of DNA Elements (ENCODE) 
project[129]. 
4.3 Results  
4.3.1 Variant-wise association of FMO genes and nicotine dependence 
270, 326 and 368 variants were selected for variant-wise association analysis 
in European, African American and combined sample set, respectively. 6 and 18 
(covered 262 SNPs) LD blocks were constructed in European and African American 
sample sets, respectively. Based on these LD blocks patterns, we obtained the 
significant thresholds for variant-wise analysis were 3.6×10
-3
, 1.25×10
-3
 in European 
American and African American sample set, respectively. We chose the most 
conservative one as our P value threshold in analysis (1.25×10
-3
). Multiple different 
significant variants were identified in European and African American datasets (Table 
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4.2, Figure 4.1). A cluster of significant variants were identified in European 
American individuals (with most significant SNP rs6674596, P=0.0004, OR=0.67, 
FMO1). In African American individuals, we identified several clustered significant 
variants (with the most significant SNP rs6608453, P=0.001) in pseudo gene FMO6P.  
4.3.2 Haplotype based and gene-wise association of FMO genes and nicotine 
dependence 
We performed haplotype based analyses in European and African American 
dataset separately. The P value thresholds were decided by Bonferroni correction and 
thus were different for each dataset. We utilized 0.008(0.05/6) and 0.0025 (0.05/20) 
as P value threshold for European and African American dataset, respectively. No 
significant signals were identified through haplotype based analyses. Gene-wise 
association analyses mainly focused on rare and/or low frequency variants in our 
dataset. Although we have tried multiple analytical schema (combination of different 
MAF threshold and region definitions), no significant association signals were found 
in this analysis (Table 4.3).    
4.3.3 Bioinformatics analysis  
Proteins that show evidence for interaction with proteins encoded by FMO1, 
FMO3 and FMO6P were extracted from STRING (Figure 4.2-4.4). Both FMO1 and 
FMO3 have a strong relation with a variety of genes belong to CYP gene families. 
FMO6P, however, as a pseudo gene, only showed limited evidence related with 
PRSS16. We explored the top significant variants (rs6674596 and rs608453) in 
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Regulome DB to investigate their potential biological significance. Regulome DB has 
its own scoring system to measure the biological significance of a variant. The range 
of the scores is from 1-6, and the smaller the score is, the more evidence that indicate 
this variant has biological significance. Rs6674596 has a Regulome DB score of 5, 
and it located within a DNase hypersensitive area of assayed in multiple cell types. In 
addition, this variant also located at a sequence motif region (HNF1). Rs608453 has a 
Regulome DB score of 6. It also located in the a sequence motif (Cdx). No expression 
quantitative trait loci (eQTL) or transcription factor (TF) binding related evidence 
were shown for neither variants.  
4.4 Discussion 
As part of a large scale targeted sequencing study focusing on 
nicotine-dependent/nondependent smokers, our aim was to test the hypothesis that 
genetic polymorphisms of flavin-containing monooxygenase genes contribute to the 
risk of nicotine dependence. The underlying rationale of this study is based on the fact 
that flavin-containing monooxygenase genes are key genes of the nicotine metabolism 
pathway [118]. FMO1 may play a role in nicotine metabolism and contributed to the 
nicotine level in brain organ [130], and FMO3 encodes flavin-containing 
monooxygenase 3 (encoded by FMO3), which can metabolize a small percentage of 
nicotine into nicotine N’-oxide [118]. We studied both rare and common variants in 
FMO1, FMO3 and FMO6P through large scale targeted sequencing.  
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A number of common variants in FMO1 were identified to be significantly 
associated with nicotine dependence, and we noted that there was an ethnic-specific 
pattern. We identified a cluster of significant variants in FMO1 in the European 
Americans. The most significant variant was rs6674596 (P=0.0004, OR=0.67, 
MAF_EA=0.135, MAF_AA=0.463). However, this significant result was not 
replicated in our African American dataset (P=0.9325, OR=1.01). The association 
signals for FMO1 have been reported by Hinrichs et al [120]. Several significant 
SNPs reported in that paper, including rs742350 and rs1126692, were also identified 
to be significant in our study. Considering both studies utilized COGEN samples, our 
results on the common SNPs basically replicated Hinrichs’ results. In addition to the 
significant findings in European American sample set, we also identified a set of 
significant variants located on gene FMO6P from the African American dataset (with 
the most significant SNP rs6608453, P=0.001, MAF_AA=0.097, MAF_EA=0.192). 
Just like significant variants were only identified in European Americans, this 
significant signal of FMO6P was only identified in African Americans but failed to be 
replicated in European Americans (P= 0.1109, OR=1.17). No significant SNPs were 
identified from the combined sample set, although in the combined samples set the 
sample size almost doubled with a correspondent increment in statistical power. The 
reasons behind this ethnic-specific pattern might be complex, and the most plausible 
one is differences in the regional LD structure between the two racial/ethnic groups. 
This difference might mean the surrogate SNPs miss the signal created by the real 
underlying susceptible variants in a specific set of samples.  
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One major advantage of our targeted sequencing study is that we can examine 
every possible DNA variations in our targeted regions and conducted association 
analysis thoroughly. However, in this study, we did not detect significant association 
between the rare variants and nicotine dependence, although we systematically tried 
many combinations of statistical methods, MAFs, region definitions and sample sets. 
The most significant rare variant set was identified for gene FMO1 with region 
definition of ―gene region‖ and MAF<0.01 in African Americans (P=0.0636). The 
lack of significant findings for rare variants suggests that the significant associations 
for common SNPs are not simply surrogates for rare variant associations (synthetic 
associations) [131].  
We found it interesting to examine the functional significance of the 
significant common SNPs we identified. All of the significant common SNPs are 
located either in introns or outside the gene. Therefore, if these significant common 
SNPs alter function, it is not by changing protein structure. The most significant SNP 
in FMO1, rs6674596, is located within a DNase hypersensitive area of assayed in 
multiple cell types, and most of the regulatory regions and some promoter regions 
tend to be DNase sensitive. This suggests that this SNP might have an effect on the 
expression of gene FMO1. Nevertheless, without further evidence from biological 
experiments, it is still too early to explain this association signal. 
FMO6P is a pseudo gene which means that this gene cannot be properly 
expressed as a protein, and it is probably because it is unable to produce a full length 
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transcript [132]. FMO6P is reported to have significant sequence homology with 
FMO3 [132]. Previous studies have set up direct links of SNPs in FMO6P with 
chronic allograft dysfunction [133] and pharmacokinetic characteristics of sulindac 
sulfide in premature labor [134]. One interesting note for these previous studies is that 
the significant findings of FMO6P are always accompanied with significant findings 
from FMO3, and at least in one study [135] , the significant SNP of FMO6P is in 
complete LD with significant SNP of FMO3. This suggests that the significant hit in 
FMO6P might be a surrogate for some true underlying signal in FMO3. However, in 
our study, although some SNPs of FMO3 are indeed in complete LD with the 
significant SNPs of FMO6P, the whole significant SNP cluster is located in the 
FMO6P region (Figure 4.1). On the other hand, if the signal we identified in FMO6P 
is not the surrogate for effects of SNPs in FMO3, but has an independent effect on 
nicotine dependence, then further research will be needed to clarify the underlying 
function of FMO6P. 
A major strength of our study is that, unlike most of the common SNP based 
association studies, is that we implemented a targeted sequencing technology for 
genotyping of our study subjects. This enables us to consider both common and rare 
variants within the three gene regions. Additionally, this study design enabled us to 
analyze both SNVs and indels which are often omitted in SNP based study designs. 
However, there are also some limitations to this study that need to be noted. Firstly, 
we lack replication for our significant findings. The design using two racial/ethnic 
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groups in our study enabled us to use as the two datasets as replication set for each 
other. However, significant findings in the European American dataset were not 
confirmed in the African American dataset. In addition, our sample size limited the 
statistical power to detect potential modest effects of SNPs. This is a common 
challenge, especially when using study designs, such as targeted sequencing, which 
generate genotype data at many variants, leading to multiple comparisons and 
corresponding stringent significance requirements. Future work to address this 
challenge would be to combine multiple sequenced datasets using meta-analysis; such 
approaches have been productive for GWAS of complex traits and have yet to be fully 
leveraged for sequencing studies and rare variant analyses. 
In summary, we tested the genetic effects of three flavin-containing 
monooxygenases genes (FMO1, FMO3 and FMO6P) on nicotine dependence by 
performing targeted sequencing on 2,852 nicotine-dependent and non-dependent 
smokers. We performed both variant-level and gene/region-level analyses to examine 
the genetic association of rare, low frequency and common variants within these 
region and nicotine dependence, and both SNVs and indels. We identified significant 
association signals for gene FMO1 and FMO6P. Replications of our finds in other 
ethnic groups were needed in the future. Most of the significant variants identified 
were SNPs located within intron regions or with unknown functional significance, 
indicating a need for future work to understand the underlying functional significance 
of these signals.  
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4.5 Figures 
 
Figure 4.1 Regional association plots of FMO1-FMO3-FMO6P genomic region based on European Americans and African Americans. a) 
European Americans and b) African Americans. The blue dash lines are the –log10(P-value) threshold used in our study(1.25×10
-3
). 
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Figure 4.2 Protein-protein interaction network of FMO1. 
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Figure 4.3 Protein-protein interaction network of FMO3. 
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Figure 4.4 Protein-protein interaction network of FMO6P. 
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4.6 Tables 
Table 4.1 Characteristics of study subjects 
  
Nicotine dependent Non-dependent 
Sample, n 
 
1,583 1,237 
Gender 
   
 
Female 901(59%) 805(65%) 
 
Male 682(41%) 432(35%) 
Ethnicity 
   
 
European American 730(46%) 702(57%) 
 
African American 853(54%) 535(43%) 
Age in year, mean (range) 
 
37(25-45) 36(25-45) 
FTND score*, mean (range) 
 
6.34 (4-10) 0.16(0-1) 
*FTND is the Fagerström Test for Nicotine Dependence.  
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Table 4.2 Significant signals in variant-wise association analysis.  
CHR VAR GENE POS A1 OR_EA P_EA MAF_EA OR_AA P_AA MAF_AA 
1 rs11812044 FMO6P 171115567 A 1.16 0.1232 0.19 0.65 0.0012 0.10 
1 rs17565793 FMO6P 171116267 C 1.16 0.1232 0.19 0.65 0.0012 0.10 
1 rs17623477 FMO6P 171116304 C 1.16 0.1232 0.19 0.65 0.0012 0.10 
1 rs7051747 FMO6P 171116550 G 1.16 0.1232 0.19 0.65 0.0012 0.10 
1 rs7066454 FMO6P 171116603 T 1.16 0.1232 0.19 0.65 0.0012 0.10 
1 rs7063044 FMO6P 171116760 T 1.16 0.1232 0.19 0.65 0.0012 0.10 
1 rs6608453 FMO6P 171117140 T 1.17 0.1109 0.19 0.64 0.0010 0.10 
1 rs6608454 FMO6P 171117170 C 1.16 0.1232 0.19 0.65 0.0012 0.10 
1 rs12726624 FMO1 171231630 G 0.67 0.0004 0.13 1.03 0.7385 0.47 
1 rs17581251 FMO1 171232446 T 0.67 0.0011 0.12 0.98 0.8685 0.08 
1 rs28360379_indel FMO1 171234851 A 0.68 0.0006 0.13 0.99 0.8698 0.43 
1 rs6674596 FMO1 171235088 T 0.67 0.0004 0.14 1.01 0.9325 0.46 
1 rs13376631 FMO1 171235742 G 0.69 0.0009 0.13 1.00 0.9831 0.43 
1 rs12094878 FMO1 171243863 C 0.69 0.0012 0.14 1.04 0.6315 0.47 
1 rs12062692 FMO1 171245579 G 0.69 0.0009 0.14 0.97 0.7002 0.48 
1 rs7539057 FMO1 171248614 A 0.70 0.0012 0.14 0.95 0.4840 0.42 
1 rs742350 FMO1 171250044 T 0.69 0.0012 0.14 1.03 0.6911 0.46 
1 rs12091482 FMO1 171251509 T 0.70 0.0012 0.14 0.94 0.4723 0.42 
1 rs10399952 FMO1 171251663 G 0.69 0.0011 0.14 0.95 0.5037 0.42 
1 rs10399602 FMO1 171251876 C 0.70 0.0012 0.14 0.95 0.4840 0.42 
1 rs7519999 FMO1 171251958 G 0.70 0.0012 0.14 0.95 0.4840 0.42 
1 rs1126692 FMO1 171252287 G 0.70 0.0012 0.14 0.93 0.3914 0.46 
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1 rs12092985 FMO1 171252537 A 0.70 0.0012 0.14 0.95 0.4840 0.42 
1 rs10912714 FMO1 171253037 G 0.69 0.0011 0.14 0.95 0.4840 0.42 
1 rs12059179 FMO1 171255346 T 0.70 0.0012 0.14 0.91 0.2620 0.39 
Significant findings were highlighted in bold. 
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Table 4.3 Full results of gene-wise association analysis. 
Gene Population MAF Region  SKAT Burden 
FMO1 European American <0.05 gene region 0.8072 0.2071 
   
functional region 0.8003 0.2857 
  
<0.01 gene region 0.5491 0.1463 
   
functional region 0.8020 0.2657 
 
African American <0.05 gene region 0.2905 0.2146 
   
functional region 0.8675 0.2844 
  
<0.01 gene region 0.0636 0.2481 
   
functional region 0.9902 0.8136 
 
Combined <0.05 gene region 0.2030 0.4330 
   
functional region 0.4013 0.4399 
  
<0.01 gene region 0.5486 0.7550 
   
functional region 0.7578 0.6936 
FMO3 European American <0.05 gene region 0.4270 0.2791 
   
functional region 0.9838 0.3735 
  
<0.01 gene region 0.8539 0.6863 
   
functional region 0.8246 0.1389 
 
African American <0.05 gene region 0.7460 0.5758 
   
functional region 0.3600 0.6912 
  
<0.01 gene region 0.9340 1.0000 
   
functional region 0.5992 0.3285 
 
Combined <0.05 gene region 0.1351 0.9251 
   
functional region 0.8212 0.5602 
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<0.01 gene region 0.1902 0.0691 
   
functional region 0.6783 0.4064 
FMO6P European American <0.05 gene region 0.3707 0.3239 
   
functional region 0.2326 0.1856 
  
<0.01 gene region 0.2917 1.0000 
   
functional region 0.0948 0.3778 
 
African American <0.05 gene region 0.7999 0.3774 
   
functional region 0.2711 0.6926 
  
<0.01 gene region 0.8139 0.3701 
   
functional region 0.1175 0.6725 
 
Combined <0.05 gene region 0.6998 0.7264 
   
functional region 0.3588 0.5644 
  
<0.01 gene region 0.5938 0.1462 
   
functional region 0.7372 0.5602 
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Chapter 5: Evaluation and optimization 
of multiple centrality measures in human 
protein-protein interaction network 
5.1 Introduction 
Human gene networks are graphical representations of the interactions between 
the genes. In a human gene network, genes are represented as nodes and the relationships 
among them as edges. Human gene networks can be divided into three categories: 1) 
Human gene networks derived from the curated knowledge; 2) Human gene networks 
based on the experimental data of physical interactions, and 3) those that are inferred 
from high-throughput data [136]. Centrality is a key indicator that identifies the most 
important vertices within a graph. To quantify centrality, four major measurements have 
been proposed: 1) Degree centrality, which simply counts the number of interactions to a 
node; 2) Betweenness centrality, where nodes which fall in the shortest path of other 
nodes have high betweenness; 3) Closeness centrality, which is related to the topology of 
the nodes in a network; and 4) Eigenvector centrality which ranks the nodes in a network 
based on its integrating neighbors [137]. Despite some early studies [138][139] that 
utilize the simplest degree centrality measure, most of the recent research projects have 
implemented the eigenvector centrality measure, such as algorithms modified from the 
Google PageRank algorithm, to evaluate the importance of a gene in a gene network 
[35][140]. However, research questions such as to what extent these centrality measures 
72 
can represent the functional significance of genes or whether any of these centrality 
measures outperformed others have never been seriously investigated.  
In this chapter, we aim to investigate the followed three scientific questions: 1) 
Can centrality reflect the biological significance of genes in a general human gene 
network? 2) Among these four commonly used centrality measures, does any of them 
outperform others? 3) Will they do better if we combine several centrality measures 
together using machine learning algorithms? To answer these scientific questions, we 
construct a comprehensive human gene-gene network using protein-protein interaction 
(PPI) data.  
5.2 Materials and Methods 
5.2.1 Construction of human protein-protein interaction network 
To evaluation the efficacy of multiple centrality measures as indicators of the 
biological significance of genes, we first constructed a genome-scale human gene 
network based on human protein-protein interaction (PPI) data. We extracted our PPI 
data from the STRING database [127]. As a database of known and predicted 
protein-protein interactions, STRING provides data users each protein-protein interaction 
with a confidence score. To evaluate the potential effects of the quality of PPI data to our 
study results, we constructed 4 human general dataset based on the full PPI dataset and 
PPI dataset with top 75%, 50% and 25% high confidence score, respectively.   
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5.2.2 Calculation of multiple centrality measures 
Four measurements of centrality were calculated based on our general human 
gene network, including degree centrality, betweenness centrality, closeness centrality 
and pagerank centrality. Degree centrality is simply the number of adjacent edges to each 
node. Betweenness centrality equals to the number of shortest paths from all vertices to 
all others that pass through that node. Closeness centrality is defined as the reciprocal of 
the farness which is the sum of distances of a node to all other nodes in a network. 
Pagerank centrality ranks the nodes in a network based on its integrating neighbors. The 
R package igraph was utilized to perform the construction of human network and the 
calculations of these centrality measures [141].  
5.2.3 Extraction of human essential gene sets 
To evaluate the centrality measures as indicators of the functional significance of 
human genes, besides the general human gene network we constructed, we also need a set 
of genes to serve as ―true answers‖, which means that we are sure that these genes should 
be biologically essential to human beings. We prepared our human essential gene sets in 
the following three ways (resulting in four gene sets):  
1) Online Gene Essentiality database (OGEE). OGEE is an online database that records 
both experimentally tested essential and non-essential genes [142].Two categories of 
essential genes, large-scale experiments based and text-mining based, were recorded 
in the OGEE database. We extracted these two sets of essential human genes from 
this database, and they were marked as OGEE.experiment and OGEE.textmining in 
the following, respectively. 
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2) Mendelian disorder related gene sets (marked as OMIM in the following). We 
extracted a set of human genes that were reported to cause mendelian disorders from 
Online Mendelian Inheritance in Man (OMIM) [143].Two files, the GeneMap file 
and MorbidMap file, were provided by OMIM. GeneMap contains the information 
that is centered by genes while MorbidMap file classified genes by their related 
phenotypes. The Mendelian disorder related genes were not specifically indicated for 
each term. To extract a potential gene list, we conducted the following filtering 
strategy: 
i. We removed those terms in both files that were tagged by ―[]‖, ―{}‖ or a question 
mark ―(?)‖.Brackets, ―[]‖, indicate "nondiseases," mainly genetic variations that 
lead to apparently abnormal laboratory test values but not disorders. Braces, ―{}‖, 
indicate mutations that contribute to susceptibility to multifactorial disorders or to 
susceptibility to infection. A question mark, ―?‖, before the disease name 
indicates an unconfirmed or possibly spurious mapping.  
ii. For the GeneMap file, we only selected those terms with an indicator ―C‖ 
(confirmed), which means this association was observed in at least two 
laboratories or in several families. 
iii. For MorbidMap, we only selected those terms with an indicator ―(3)‖, which 
means the the molecular basis of the disorder is known. 
iv. We then merged the two gene lists obtained from the GeneMap file and 
MorbidMap file, and obtained the OMIM gene set. 
3) Empirical gene sets (marked as ExAC in the following). This is an essential gene set 
that is extracted based on the Exome Aggregation Consortium (ExAC) data.ExAC 
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and includes exome sequencing data from a wide variety of large-scale sequencing 
projects spanning 60,706 unrelated individuals[144]. We extracted a set of essential 
genes by selecting genes that do not contain any destructive variants. The basic 
rationale of this gene set is that if a gene is very important and essential for human 
beings, disruptive mutations of this gene cannot be found in people with no severe 
pediatric disease. We utilized ExAC data set to obtain this gene set in the following 
filtering strategy:  
i. A standard quality control (QC) process was applied to the ExAC dataset, only 
variant calls with quality indicating as ―PASS‖ were included in the following 
study. 
ii. We removed those genes that contained frameshift indels in any of the 60,706 
individuals and this step reduced the gene number to 4,465. Frameshift indels are 
very disruptive mutations that may completely disable the gene function. 
iii. We removed genes in major histocompatibility complex (MHC) regions. The 
rationale of this step is that there are a lot of repetitive sequences in this region 
and this severely affected the quality of the sequencing experiment. Therefore, the 
genes we identified in MHC regions that contain no frameshift indels may not be 
because that these genes are important, it may be just because of the low quality 
of sequencing. We eliminated those variants with low quality during the QC 
process. After applying this strategy, there are 2,760 genes left. 
iv. We assumed the length of coding sequence (CDS) of a gene might affect the 
chance that a frameshift mutation occurs within the gene. Therefore, we ranked 
the 2,760 genes by their length of CDS and only included the 1,200 genes with 
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shorter CDS.  
The basic rationale behind the selection of essential gene sets is that we want to 
collect a set of genes that are ―functionally significant‖ for human beings (so they can 
serve as the ―true answer‖ in ROC analyses).  It is art more than science to select these 
gene sets because there is no universal standard to determine what kind of genes can be 
considered ―functionally significant‖. Lethality is the first potential criterion. However, it 
is difficult to apply this standard directly due to ethical issues. To overcome this 
difficulty, we utilized two methods. The first one is the experimental method. We can 
obtain a set of genes that were experimentally proven to be lethal when knocked out in 
model organisms, and then map those genes back to the human genome and extract the 
homologous genes. This defines to the two gene sets we obtained from OGEE. Another 
one is the observational method. We simply examine the genomes data of human 
populations to examine whether there are any genes without disruptive mutations. This 
defines the empirical gene set (ExAC). In addition to lethality, a list of causal genes of 
mendelian disorder might be another choice for a set of functionally significant genes. 
5.2.4 Comparisons and evaluations of different centrality measures 
To compare the effecacy of these four measurements of centrality as predictors of 
functional significance of genes in human gene network, we made receiver operating 
characteristic (ROC) curves in the following ways: 
1) We checked the four essential gene sets by each definition of centrality measure. 
2) We checked the four different centrality measure for each essential gene set. 
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5.2.5 Logistic regression model by combination of multiple centrality measures 
To evaluate whether there is an improvement using a combined score of different 
combinations of these centrality measures, we constructed a series of logistic regression 
models. Due of the severe multicollinearity among these four degree centrality measures 
(Figure 5.1), we fitted our model using a penalized regression technique. The 10-fold 
cross-validation approach was used to assess the performance of these prediction models. 
We calculated the area under curve (AUC) as a major indicator for comparisons of the 
models. Regression model fitting and model comparisons were conducted by R package 
glmnet [145].  
5.3 Results 
5.3.1 Human protein-protein interaction network and essential gene sets 
We constructed a general human gene network that covered 18,199 human protein 
coding genes using the full PPI data from STRING. This gene network covered 82.6% of 
human genes. We obtained four essential gene sets, including OGEE.experiment (1,511), 
OGEE.textmining (1,502), OMIM (1,244) and ExAC (1,200) gene set by the methods 
described above. The number of genes for each gene set and the overlaps are shown in 
Table 5.1. From this table, we can see that the four essential gene sets we extracted were 
basically independent from each other with limited overlaps. The following main results 
were conducted using human gene network constructed from the full PPI data 
downloaded from STRING. Most of these results were validated in the other three 
networks that were constructed with less but higher quality data (using 75%, 50% and 25% 
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of the PPI data). We have summarized the information of these four networks in Table 
5.2. 
5.3.2 Comparisons of the four centrality measures as indicators of biological 
significance 
The centrality measures of the four essential gene sets were calculated based on 
network constructed from full PPI data and shown in Figure 5.2. ANOVA analyses 
indicated the differences in centrality of the five gene sets (four essential gene sets and 
one random selected gene set) were significant in all of the four centrality measures (for 
degree, closeness and pagerank centrality P<2×10
-16
; for betweenness centrality, 
P=7.91×10
-16
).  In general, all of these four essential gene sets had higher centrality 
compared to the randomly selected gene set for all four centrality measures. Two 
essential gene sets that were extracted from OGEE (experiment and textmining) had 
higher centralities compared to ExAC and OMIM gene sets. ROC curves that compared 
the average centralities of these four essential gene sets were shown in Figure 5.3. The 
centralities of the four essential gene sets were calculated based on network constructed 
from 75%, 50% and 25% PPI data were shown in Figure 5.4- 5.6.  
5.3.3 Comparison and optimization of the four centrality measures using logistic 
model 
The four centrality measures were compared using ROC curve for each essential 
gene sets (Figure 5.7). As we can see from this figure that, for all these four essential 
gene sets, there is no significant difference among the centrality measures. None of these 
centrality measures outperformed the others as a predictor of the essentiality of genes in 
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our general human gene network. This result was validated in human gene network 
constructed using 25%, 50% and 75% PPI data, and these results were shown in Figure 
5.8-5.10. The logistic models were evaluated using AUC measurements. The AUC plot 
based on four essential gene sets were summarized in Figure 5.11. As we can see from 
figure 3, in general, models including more centrality measures performed better (except 
for OMIM gene set). However, this improvement was limited. The largest improvement 
in AUC was around 0.05. Detailed information of AUC measures for different 
combinations of centrality measures were summarized in Table 5.3.  
5.4 Discussion  
Previous genome-wide studies have shown that disrupted hub protein, protein that 
locates at center position in a PPI network, is more likely to have lethal effect than a 
non-hub protein, and this phenomenon is sometimes described as ―centrality-lethality rule‖ 
[146]. Our findings substantiated these previous observations. All of these four essential 
gene sets had significantly higher centralities compared to a gene set randomly selected. 
Another interesting observation is that the average centrality measures of these four 
essential gene sets showed a gradient pattern. In general, essential gene sets extracted 
from OGEE had highest average centrality, and OMIM gene set was slightly lower, while 
ExAC gene set had the lowest average centrality. This pattern can be explained by the 
differences of the potential functional significance among these essential gene sets. 
OGEE gene sets were based on the experimental evidence of lethality in model 
organisms, and the disruption of these genes might have lethal effects in human beings. 
On the other hand, genes in OMIM gene set were causal genes of human mendelian 
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disorders, and in most situations, disrupting these genes will cause mendelian disorders 
but not to be lethal. In this sense, the OGEE gene sets should be more biologically 
significant compared to genes in OMIM gene set. These evidence indicated that greater 
biological significance implies average higher centrality in a general PPI network. 
Another feature of our study that is different from previous research is that we provided a 
tool to quantify and evaluate the efficacy of the centralities as predictors of functional 
significance of genes in human gene network.   
One thing interesting to note is the performance of ExAC gene set in our analyses. 
The ExAC gene set was expected to have similar properties to the OGEE gene set 
because both of them were based on the lethality standard as described in the method part. 
However, the average centralities of ExAC gene set were the lowest among all of these 
four gene sets. This might be due to two reasons. The first one is the ExAC gene set was 
extracted based on around 60,706 individuals, and this sample size might not be large 
enough to rule out some non-significant genes. In addition, several arbitrary criteria used 
during the filtering process might increase the chance of the exclusion of some important 
genes. For example, we utilized the length of coding sequence (CDS) as a filtering 
criterion to reduce its potential effects. This criterion can rule out many small trivia genes, 
however, as an arbitrary criterion, it might also exclude some potential functionally 
significant genes.  
The four centrality measures commonly used in network analysis constitute 
different mathematical computations on the same underlying data. Degree centrality, for 
example, is very easy to calculate, but betweenness and closeness centralities are 
computational intensive especially when the adjacency matrix involved are big. Despite 
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these differences in computational level, previous researchers have noticed the statistical 
correlations among multiple centrality measures in a social network [147]. In our study, 
we also observed a pattern of high correlation among the four centrality measures using 
our general human gene network. In addition, this correlation property might also 
contribute to the similarity of the performance of these centralities serving as predictors 
as functional significance of genes. This high correlation property might also be the 
reason that combinations of these centrality measures could only make a very limited 
improvement for the performance of the logistic models. This indicates that the 
development of multiple measures may be somewhat redundant, and they might perform 
similarly in statistical analyses.  
In this study, we have showed that genes with high centralities were enriched with 
essential genes.  A potential limitation of this study is that we only explored the property 
of gene centrality in a general human gene network which covered most of the human 
protein coding genes. The biological mechanisms are very complex and a general human 
network cannot provide enough resolution to scrutinize detailed aspects of the enrichment 
pattern of functional genes. Furthermore, in this study, we only investigated the gene sets 
that are essential to human beings, and it might be more interesting to examine the 
centrality property of genes that are susceptible to complex disorders/traits. Therefore, for 
future study, it might be more fruitful for researchers to construct some functional 
specific sub-networks and focused on susceptible genes of complex disorders/traits.  
To conclude, in this study we have showed that there is a connection between the 
essentiality and centrality of human genes. A pattern of strong correlations was identified 
among the four commonly used centrality measures for a general human PPI network and 
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the performance of each centrality measure was similar to others serving as predictors of 
the essentiality of genes. The improvement of the prediction models was limited when 
combined several different centrality measures.  
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5.5 Figures 
 
Figure 5.1 Scatter matrix for the four measurements of centrality. The outlier in this plot 
is gene ubiquitin C(UBC). It was removed in the following model fitting. 
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Figure 5.2 Comparison of the average centralities of the four essential gene sets. a) 
degree centrality. b) closeness centrality. c) betweenness centrality. d) pagerank centrality. 
A gene set tagged as ―Random‖ was also included for the comparison. This gene set 
(with 850 genes) was randomly selected and was exclusive from the other four gene sets. 
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Figure 5.3 ROC curves of the average centralities aomng the four essential gene sets. a) 
degree centrality. b) closeness centrality. c) betweenness centrality. d) pagerank centrality. 
The X and Y axis are false positive rate (FPR) and true positive rate (TPR), respectively. 
  
86 
 
Figure 5.4 Comparison of the average centralities of the four essential gene sets using 
network constructed by 25% PPI data. a) degree centrality. b) closeness centrality. c) 
betweenness centrality. d) pagerank centrality. A gene set tagged as ―Random‖ was also 
included for the comparison. This gene set (with 850 genes) was randomly selected and 
was exclusive from the other four gene sets. 
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Figure 5.5 Comparison of the average centralities of the four essential gene sets using 
network constructed by 50% PPI data. a) degree centrality. b) closeness centrality. c) 
betweenness centrality. d) pagerank centrality. A gene set tagged as ―Random‖ was also 
included for the comparison. This gene set (with 850 genes) was randomly selected and 
was exclusive from the other four gene sets. 
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Figure 5.6 Comparison of the average centralities of the four essential gene sets using 
network constructed by 75% PPI data. a) degree centrality. b) closeness centrality. c) 
betweenness centrality. d) pagerank centrality. A gene set tagged as ―Random‖ was also 
included for the comparison. This gene set (with 850 genes) was randomly selected and 
was exclusive from the other four gene sets. 
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 Figure 5.7 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network. a) OGEE.experiment. b) OGEE.textmining. c) 
OMIM. d) ExAC. 
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Figure 5.8 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network constructed by 25% high quality PPI data. a) 
OGEE.experiment. b) OGEE.textmining. c) OMIM. d) ExAC.  
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Figure 5.9 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network constructed by 50% high quality PPI data. a) 
OGEE.experiment. b) OGEE.textmining. c) OMIM. d) ExAC.  
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Figure 5.10 ROC curves for evaluating the four centrality measures as predictors of 
essentiality in human gene network constructed by 75% high quality PPI data. a) 
OGEE.experiment. b) OGEE.textmining. c) OMIM. d) ExAC.  
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Figure 5.11 AUC plot based on four essential gene sets. a) OGEE.experiment. b) 
OGEE.textmining. c) OMIM. d) ExAC. Numbers at the top of each plot indicated the 
number of variables included in regression models. Only largest AUC measures were 
shown in this plot for different variable combinations. 
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5.6 Tables  
Table 5.1 Number of genes in each essential gene sets and the pattern of overlaps. 
 
OGEE.experiment (%) OGEE.textmining (%) OMIM (%) ExAC (%) Covered by Network (%) 
OGEE.experiment 1,511 (100) 298 (19.8) 170 (13.9) 150 (12.5) 1,441 (95.4) 
OGEE.textmining 298 (19.7) 1,502 (100) 302 (24.7) 133 (11.1) 1,455 (96.9) 
OMIM 170 (11.3) 302 (20.1) 1,224 (100) 110 (9.2) 1,191 (97.3) 
ExAc 150 (9.9) 133 (8.9) 110 (9.0) 1,200 (100) 1,140 (95.0) 
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Table 5.2 Summarized information of the four human gene network. 
 
Combined Score threshold Number of genes covered (% to human genome) 
Network 100 / 18199 (82.6) 
Network 75 175 18173 (82.5) 
Network 50 212 18146 (82.4) 
Network 25 317 18076 (82.1) 
 
  
96 
Table 5.3 Detail information of AUC measures for different models 
Models OGEE.experiment OGEE.textmining OMIM ExAc 
degree (1) 0.7345 0.7409 0.6703 0.5958 
closeness (2) 0.7461 0.7483 0.6856 0.6131 
betweenness (3) 0.6953 0.7280 0.5569 0.5324 
pagerank (4) 0.7323 0.7440 0.6763 0.5976 
(1)+(2) 0.7456 0.7479 0.6841 0.6135 
(1)+(3) 0.7337 0.7400 0.6682 0.6001 
(1)+(4) 0.7353 0.7637 0.7010 0.5971 
(2)+(3) 0.7459 0.5514 0.6836 0.6131 
(2)+(4) 0.7322 0.7492 0.6812 0.6133 
(3)+(4) 0.7460 0.7432 0.6720 0.5986 
(1)+(2)+(3) 0.7456 0.7489 0.6848 0.6122 
(1)+(2)+(4) 0.7457 0.7859 0.7154 0.6109 
(1)+(3)+(4) 0.7296 0.5390 0.7043 0.5986 
(2)+(3)+(4) 0.7459 0.7496 0.6805 0.6122 
(1)+(2)+(3)+(4) 0.7484 0.7882 0.7250 0.6115 
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Chapter 6: Centrality pattern of 
susceptibility genes to complex disorders 
in functional specific protein-protein 
interaction sub-networks 
6.1 Introduction 
The biological processes in humans are regulated through complex molecular 
networks. One of the most important features of such networks is that the effect caused 
by blocking one pathway within a network can be bypassed through some other ―back 
door pathways‖. Accordingly, if a gene loses its function because of mutation, and if it is 
not located at the central position of a gene network, it may have little impact to the 
biological process due to the bypassing effects. On the other hand, if this gene has a 
relatively high centrality in the gene network, the loss of its function may block several 
pathways simultaneously and therefore no bypassing pathway can be used to supplement 
its loss of function. In chapter five, we have shown the centrality distribution of several 
essential gene sets in a general human gene network. In this chapter, we will present what 
the centrality distribution pattern would be in function specific sub-networks for several 
sets of susceptibility genes contributing to complex disorders.  
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6.2 Methods and Materials  
6.2.1 Construction of human PPI network and calculation of centrality 
We utilized known and predicted PPI data from STRING (http://string-db.org/) to 
construct our human PPI network [127]. Besides the human PPI network constructed 
using the full dataset from STRING, we also utilized the quality score provided by 
STRING to construct human PPI network with only 50% of the STRING data with 
higher quality score to validate the results we obtained from the network constructed 
using full PPI data. Centrality of genes was measured by degree centrality [148]. R 
package igraph was utilized for network construction and related analyses [141].  
6.2.2 Construction of brain function related sub-networks 
RNA-sequence data from the database The Human Protein Atlas 
(http://www.proteinatlas.org/) were utilized to construct brain function related 
sub-networks [149]. The number of Fragments Per Kilobase gene model and Million 
reads (PKFM) values of cerebral cortex were utilized as a filter criterion, and a series of 
brain function related sub-networks were constructed based on genes that have a PKFM 
value in cerebral cortex greater than a certain threshold. We labeled the human general 
PPI network as network No.0. Then, genes that have a PKFM value in cerebral cortex 
greater than 0.1×average PKFM in all human tissues (data of 44 tissues were recorded in 
the database) were extracted and constructed as sub-network No. 1. Genes that have a 
PKFM value in cerebral cortex greater than 0.2×average PKFM in all human tissues were 
extracted and constructed as sub-network No. 2, and so on so forth. 30 sub-networks 
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were constructed, and the sub-networks with the larger number have fewer genes but 
these genes were more related with brain activity.  
6.2.3 Extraction of susceptibility genes to complex disorders 
Susceptibility genes of 25 complex disorders were extracted from the GWAS 
catalogue (http://www.ebi.ac.uk/gwas/) [7]. Reported genes were extracted from the 
GWAS catalogue for each disorder. These 25 complex disorders can be classified into 
seven classes including neurodegenerative disorders, psychiatric disorders, liver related 
disorders, skin related disorders, kidney related disorders, pancreas related disorders and 
lung related disorders, and the last five classes can be combined as non-brain related 
disorders (Table 6.1). Additionally, an essential gene set was also extracted from online 
gene essentiality database (OGEE, http://ogeedb.embl.de/) as a comparison set. This 
essential gene set was collected based on large scale experiments on model organisms 
with lethality as an important criterion for recruiting them. To control potential 
confounding factors, some disorders that were difficult to be defined as brain or 
non-brain related disorders (such as obesity and substance addiction) were not included in 
this study. In addition, this study mainly focused on complex disorders as a qualitative 
variable, genes that only affect quantitative medical indicators of the disorders were not 
included. 
6.2.4 Statistical analyses 
Two levels of enrichment pattern of susceptibility genes to complex disorders 
were analyzed and compared among all these three major categories of complex disorders. 
The first level is on the number of genes and the second level is the average/median 
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centrality of genes. We utilized a 1,000 permutation technique to compare these 
enrichment patterns of the three complex disorder categories in a series of brain function 
related sub-networks. For the centrality level, null distribution of the average/median 
centrality for each gene set was created through permutation in each sub-networks and 
the general human network. Then the P values of the observed average/median centrality 
of each gene set were calculated. 
6.3 Results 
6.3.1 Construction of general human networks and brain function related 
sub-networks 
A total of 31 human PPI gene networks were constructed (1 general network and 
30 brain function related sub-networks). Summarized information of these gene networks 
are shown in Table 6.2. The largest network, network No. 0 is a general human PPI gene 
network with 18,041 genes. The smallest sub-networks, network No. 30, is constructed 
by genes that were 3 times expressed in cerebral cortex comparing to the average level. It 
only included 1,774 genes but these genes were highly expressed in brain and are highly 
related to brain activity.  
6.3.2 Extraction of susceptibility genes to complex disorders and their centrality in 
multiple networks 
A total of 468, 724 and 814 genes were extracted for neurodegenerative disorders, 
psychiatric disorders and non-brain related disorders (Table 6.3). In addition to these 
three gene sets, an essential gene set of 1,511 genes was also selected. The overlaps of 
genes among these three complex disorder categories were very limited. There are only 
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44 genes overlapped between neurodegenerative disorder and psychiatric disorder (9.4% 
and 6.1% of neurodegenerative disorder and psychiatric disorder, respectively). Most of 
these genes were covered by the general human PPI network (86%-91%). The degree 
centrality distribution of these three disorder categories for network 0, 6, 12, 18, 24 and 
30 are shown in Figure 6.1. Severe positive skewness and multiple outliers were 
identified for all of these 6 networks. In this situation, median seems to be a more suitable 
parameter to characterize the distribution of centrality.  
6.3.3 Enrichment pattern of susceptibility genes to complex disorders in brain 
related sub-networks 
The enrichment pattern of susceptibility genes to complex disorders in gene 
number was shown in Figure 6.2. As we can see, the two susceptibility gene sets related 
to brain showed significant differences from the permuted background, while the 
susceptibility gene sets of non-brain related disorders did not showed significant 
enrichment pattern. The enrichment in high centrality of these susceptibility genes were 
shown in Figure 6.3. Apparently, the median centrality of gene sets susceptible to 
neurodegenerative and psychiatric disorders become more and more significantly higher 
in a series of brain function related sub-networks as the genes constructed in these 
networks become more and more highly expressed in human brain. On the other hand, 
the gene set chosen by susceptibly to non-brain related disorders failed to show this 
pattern. Although it is significant in the general human network (network 0), it did not 
become more significant in more functional specific sub-networks. We also checked this 
using the average of degree centrality (Figure 6.4), and a similar pattern was obtained. To 
examine the potential effects of PPI data quality to our results, we also conducted this 
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analysis in a network constructed by 50% higher quality PPI data (Figure 6.5). The 
results indicated that the effects of quality of PPI data were limited. The centrality and 
gene number enrichment for each of these five non-brain related complex disorder classes 
are shown in Figure 6.6-6.10. The significance identified in network 0 was only identified 
in pancreas related susceptibility gene sets. The characteristics of average degree 
centrality for multiple gene sets in different sub-networks were also shown in line plots 
(Figure 6.11). The top 20 genes with higher degree centrality in sub-network 30 are 
summarized in Table 6.4.  
6.4 Discussion 
Susceptibility genes for complex disorders were believed to be peripheral in 
human gene networks, because for complex disorders there are multiple genes each with 
smaller effects, so that each gene seems not that important [38]. Our findings have shown 
that this may be true in a general human gene network, however, in functional specific 
sub-networks, the genes that confer risk to a complex disorder might have significant 
higher degree centrality. The following two features can be obtained through the 
centrality distribution patterns identified through our analyses. Firstly, compared to the 
essential genes with lethal effects in model organisms, the three complex disorder related 
gene sets have a very peripheral distribution in general human networks and the series of 
brain function related sub-networks. Secondly, for both neurodegenerative and 
psychiatric disorders, their centralities become significantly higher in the brain function 
related sub-networks. This trend becomes more and more apparent when we utilized 
more extreme criteria (PKFM values) to define the sub-networks. On the other hand, 
susceptibility genes to non-brain related disorders failed to show this pattern. These two 
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features indicated that for a certain type of complex disorder, the centrality of the 
susceptibility genes are significantly higher within properly defined sub-networks with 
specific function. Currently, there were several network based association mapping 
prioritization methods [138][139]. Our findings indicated that for these methods, the key 
point is what sub-networks were chosen, but not the fancy algorithms to incorporate P 
values with the network parameters. Because centrality of genes in a gene network only 
becomes meaningful when functional specific sub-networks are properly defined.   
Another point interesting to note is that gene BDNF is in the 20 gene list (second 
largest degree centrality) with top centrality in network 30 (Table 6.4) but has not been 
extracted as a psychiatric or neurodegenerative disorders related genes. BDNF and its 
val66-to-met mutation have been reported to be associated with several psychiatric 
disorders including schizophrenia and bipolar disorder [150][151][152].We rechecked the 
GWAS catalogue records and found that this gene was not reported as a susceptible gene 
for any psychiatric disorders to date. However, this finding may indicate that centrality 
can be utilized as a promising parameter in prioritization of candidate genes conferring 
risk to complex disorders.  
Since all of the data we utilized in this study were obtained through publically 
available databases, our study is partially confined by the completeness of current 
aggregation of relevant data. The targeted disorders of our research should be some 
complex disorders that have been intensively studied in the past, so that we can extract a 
larger number of susceptibility genes conferring risk for those disorders. In addition, 
these disorders should also be relatively more concentrated in a certain human organ or 
tissues, so it will make it easier to define a sub-network to test them and reduce the 
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potential interference effects. This condition rules out some intensively studied disorders, 
such as obesity. The two kinds of brain related disorders fitted the two conditions. Both 
psychiatric disorders and neurodegenerative disorders have been studied thoroughly in 
the past decade in GWAS and many susceptibility genes for these disorders have been 
reported. With data from the Protein Atlas, it is easy for us to define brain function 
related sub-networks and this process is totally independent of the susceptibility gene sets 
we extracted. Tissue specific gene expression data is one way to define sub-networks. 
One of a major advantage is that the sub-network will be highly functional specific to 
certain human organs or tissues. Several other public available database, including 
KEGG and Gene Ontology can be utilized to define sub-networks in the future. 
To sum up, in this study, we examined the distributions of centrality for 
susceptibility gene sets to complex disorders in multiple human gene function specific 
networks. We identified that susceptibility gene sets to complex disorder have significant 
higher centralities in properly defined function specific sub-networks.  
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6.5 Figures 
 
Figure 6.1 Distribution of degree centrality for the three disorder categories in network 0, 6, 12, 18, 24 and 30. 
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Figure 6.2 Number of genes of susceptible gene sets in multiple brain related sub-networks. 1000 permutation was performed to create 
the null distribution. 
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Figure 6.3 Median of degree centrality and their statistical significance for susceptible gene sets in multiple brain related sub-networks. 
1000 permutation was performed to create the null distribution. 
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Figure 6.4 Average of degree centrality and their statistical significance for susceptible gene sets in multiple brain related 
sub-networks. 1000 permutation was performed to create the null distribution.  
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Figure 6.5 Median of degree centrality and their statistical significance for susceptible gene sets in multiple brain related sub-networks 
using 50% higher quality score PPI data. 1000 permutation was performed to create the null distribution. 
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Figure 6.6 Gene number and centrality enrichment pattern for susceptibility genes to 
kidney related disorders in multiple brain related sub-networks. 1000 permutation was 
performed to create the null distribution.  
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Figure 6.7 Gene number and centrality enrichment pattern for susceptibility genes to liver 
related disorders in multiple brain related sub-networks. 1000 permutation was performed 
to create the null distribution.  
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Figure 6.8 Gene number and centrality enrichment pattern for susceptibility genes to lung 
related disorders in multiple brain related sub-networks. 1000 permutation was performed 
to create the null distribution.  
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Figure 6.9 Gene number and centrality enrichment pattern for susceptibility genes to skin 
related disorders in multiple brain related sub-networks. 1000 permutation was performed 
to create the null distribution.  
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Figure 6.10 Gene number and centrality enrichment pattern for susceptibility genes to 
pancreas related disorders in multiple brain related sub-networks. 1000 permutation was 
performed to create the null distribution. 
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Figure 6.11 Line plots of the average degree centrality for susceptible genes in 
sub-network 0, 6, 12, 18, 24 and 30. A random gene set of 1,000 genes was selected 
serving as control.  a. full plot; b. plot without essential gene set. 95% CI of the mean 
were added in the plot as the error bars.  
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6.6 Tables 
Table 6.1 Complex disorders selected for this research project. 
Disorder category  Disorders  
Neurodegenerative disorder  Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease, Dementia, Eplipcy 
Psychiatric disorder  
Schizophrenia, bipolar disorder, major depression, autisms, Attention Deficit Hyperactivity Disorder 
(ADHD) 
Liver related disorder* Hapetitis, Non-alcoholic fatty liver disease, Primary biliary cirrhosis, liver carcinoma  
Skin related disorder* Psoriasis, Melanoma, Acne, Non-melanoma skin cancer 
Kidney related disorder* Chronic kidney disease (CDK) 
Pancreas related disorder* Type I&II diabetes  
Lung related disorder* Lung cancer, Chronic obstructive pulmonary disease (COPD), Asthma  
*Non-brain related disorders 
117 
 
Table 6.2 FPKM thresholds and number of genes covered for the 31 networks 
constructed using STRING PPI data.  
Networks *FPKM 
threshold 
No.gene **No.covered.gene (%) 
0 - 19589 18041 (92.1) 
1 >0.1 14552 13748 (94.5) 
2 >0.2 13740 12973 (94.4) 
3 >0.3 12900 12174 (94.3) 
4 >0.4 12075 11401 (94.4) 
5 >0.5 11215 10602 (94.5) 
6 >0.6 10298 9742 (94.6) 
7 >0.7 9325 8810 (94.5) 
8 >0.8 8322 7856 (94.4) 
9 >0.9 7316 6901(94.3) 
10 >1.0 6397 6034 (94.3) 
11 >1.1 5637 5301 (94.0) 
12 >1.2 5005 4702 (93.9) 
13 >1.3 4508 4241 (94.1) 
14 >1.4 4091 3848 (94.1) 
15 >1.5 3741 3517 (94.0) 
16 >1.6 3458 3255 (94.1) 
17 >1.7 3226 3038 (94.2) 
18 >1.8 3048 2870 (94.2) 
19 >1.9 2860 2694 (94.2) 
20 >2.0 2707 2547 (94.1) 
21 >2.1 2564 2412 (94.1) 
22 >2.2 2464 2317 (94.0) 
23 >2.3 2351 2212 (94.1) 
24 >2.4 2269 2138 (94.2) 
25 >2.5 2185 2059 (94.2) 
26 >2.6 2123 2002 (94.3) 
27 >2.7 2053 1937 (94.4) 
28 >2.8 1996 1885 (94.4) 
29 >2.9 1941 1833 (94.4) 
30 >3.0 1879 1774 (94.4) 
* PKFM threshold is defined as number × average PKFM in all tissues. 
** Genes covered by STRING data.  
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Table 6.3 Information of gene numbers of the three major susceptibility genes categories  
 
Neuro (%) Psych (%) Non-brain (%) 
Covered by general PPI network 
(%) 
Neuro 468 (100) 44 (9.4) 36 (7.7) 419 (89.5) 
Psych 44 (6.1) 724 (100) 39 (5.4) 660 (91.2) 
Non-brain 36 (4.4) 39 (4.8) 814 (100) 700 (86.0) 
Neurodegenerative disorders, psychiatric disorders and non-brain related disorders were 
indicated as Neuro, Psych and Non-brain, respectively.
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Table 6.4 Top 20 genes with higher degree centrality in sub-network 30.  
Gene Ensembl ID CHR Degree Centrality Disorders Band Description 
CDK5 ENSG00000164885 7 710 - q36.1 cyclin-dependent kinase 5 
BDNF ENSG00000176697 11 664 - p14.1 brain-derived neurotrophic factor 
FYN ENSG00000010810 6 634 Neuro q21 FYN proto-oncogene, Src family tyrosine kinase 
MAPK11 ENSG00000185386 22 590 - q13.33 mitogen-activated protein kinase 11 
DIRAS2 ENSG00000165023 9 538 - q22.2 DIRAS family, GTP-binding RAS-like 2 
PPP3CA ENSG00000138814 4 536 - q24 protein phosphatase 3, catalytic subunit, alpha isozyme 
SNCA ENSG00000145335 4 526 Neuro q22.1 synuclein alpha 
RND1 ENSG00000172602 12 524 Psych q13.12 Rho family GTPase 1 
RIT2 ENSG00000152214 18 512 Neuro q12.3 Ras-like without CAAX 2 
RAP2A ENSG00000125249 13 506 - q32.1 RAP2A, member of RAS oncogene family 
RND2 ENSG00000108830 17 504 - q21.31 Rho family GTPase 2 
DLG2 ENSG00000150672 11 504 Neuro q14.1 discs, large homolog 2 (Drosophila) 
PRKCA ENSG00000154229 17 502 - q24.2 protein kinase C, alpha 
MAPK4 ENSG00000141639 18 496 - q21.1 mitogen-activated protein kinase 4 
PRKACB ENSG00000142875 1 490 - p31.1 protein kinase, cAMP-dependent, beta catalytic subunit 
SST ENSG00000157005 3 488 - q27.3 somatostatin 
GAD1 ENSG00000128683 2 478 - q31.1 glutamate decarboxylase 1 
GRIN2A ENSG00000183454 16 472 Psych p13.2 glutamate receptor, ionotropic, N-methyl D-aspartate 2A 
YWHAH ENSG00000128245 22 464 - q12.3 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 
DIRAS1 ENSG00000176490 19 462 - p13.3 DIRAS family, GTP-binding RAS-like 1 
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